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A B S T R A C T
Background
Chronic back pain is an important health problem. Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used to treat people
with low back pain, especially people with acute back pain. Short term NSAID use is also recommended for pain relief in people
with chronic back pain. Two types of NSAIDs are available and used to treat back pain: non-selective NSAIDs and selective COX-
2 NSAIDs. In 2008, a Cochrane review identified a small but significant effect from NSAIDs compared to placebo in people with
chronic back pain. This is an update of the Cochrane review published in 2008 and focuses on people with chronic low back pain.
Objectives
To determine if NSAIDs are more efficacious than various comparison treatments for non-specific chronic low back pain and if so,
which type of NSAID is most efficacious.
Search methods
We searched CENTRAL, MEDLINE, EMBASE, PubMed and two clinical trials registry databases up to 24 June 2015 for randomized
controlled trials (RCTs) published in English, German or Dutch. We also screened references cited in relevant reviews.
Selection criteria
We included RCTs (double-blind and single-blind) of NSAIDs used to treat people with chronic low back pain.
Data collection and analysis
Two review authors independently screened trials for inclusion in this Cochrane review according to the inclusion criteria. One review
author extracted the data, and a second review author checked the data. Two review authors independently evaluated the risk of bias
of all included trials. If data were clinically homogeneous, we performed a meta-analysis and assessed the quality of evidence using the
GRADE approach.
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Main results
We included 13 trials in this Cochrane review. Ten studies were at ’low’ risk of bias. Six studies compared NSAIDs with placebo, and
included 1354 participants in total. There is low quality evidence that NSAIDs are more effective than placebo, with a mean difference
in pain intensity score from baseline of -6.97 (95% CI −10.74 to −3.19) on a 0 to 100 visual analogue scale (VAS) with a median
follow-up of 56 days (interquartile range (IQR) 13 to 91 days). Four studies measured disability using the Roland Morris Disability
Questionnaire. There is low quality evidence that NSAIDs are more effective than placebo on disability, with a mean difference from
baseline of −0.85 (95% CI −1.30 to −0.40) on a scale from 0 to 24 with a median follow-up of 84 days (IQR 42 to 105 days).
All six placebo controlled studies also reported adverse events, and suggested that adverse events are not statistically significant more
frequent in participants using NSAIDs compared to placebo (RR 1.04, 95% CI 0.92 to 1.17). Due to the relatively small sample
size and relatively short follow-up in most included trials, it is likely that the proportion of patients experiencing an adverse event is
underestimated.
Two studies compared different types of non-selective NSAIDs, namely ibuprofen versus diclofenac and piroxicam versus indomethacin.
The trials did not find any differences between these NSAID types, but both trials had small sample sizes. One trial reported no
differences in pain intensity between treatment groups that used selective or non-selective NSAIDs. One other trial compared diflunisal
with paracetamol and showed no difference in improvement from baseline on pain intensity score. One trial showed a better global
improvement in favour of celecoxib versus tramadol.
One included trial compared NSAIDs with ’home-based exercise’. Disability improved more in participants who did exercises versus
participants receiving NSAIDs, but pain scores were similar.
Authors’ conclusions
Six of the 13 included RCTs showed that NSAIDs are more effective than placebo regarding pain intensity. NSAIDs are slightly more
effective than placebo regarding disability. However, the magnitude of the effects is small, and the level of evidence was low. When we
only included RCTs at low risk of bias, differences in effect between NSAIDs and placebo were reduced. We identified no difference in
efficacy between different NSAID types, including selective versus non-selective NSAIDs. Due to inclusion of RCTs only, the relatively
small sample sizes and relatively short follow-up in most included trials, we cannot make firm statements about the occurrence of
adverse events or whether NSAIDs are safe for long-term use.
P L A I N L A N G U A G E S U M M A R Y
Non-steroidal anti-inflammatory drugs for chronic low back pain
Review question
We assessed the evidence regarding the effect of non-steroidal anti-inflammatory drugs (NSAIDs) among people with chronic low back
pain. NSAIDs were compared to placebo, other NSAIDs, other drugs or other kinds of treatment.
Background
Chronic low back pain is common and causes pain and disability. NSAIDs are often used to treat people with chronic low back pain
and are available both over-the-counter and on prescription in different types and chemical entities.
Study characteristics
We collected all published randomized controlled trials evaluating the efficacy of NSAIDs until 24 June 2015. We included 13 trials
which compared NSAIDs with placebo, other NSAIDs, other drugs or other treatment in people with chronic low back pain. Six trials
compared NSAIDs with placebo, and included 1354 participants in total. Follow-up was between nine days and 16 weeks.
Key results
NSAIDs reduced pain and disability in people with chronic low back pain compared to placebo. However, the differences were small:
7 points on a 100-point scale for pain intensity. Regarding disability, people receiving NSAIDs scored 0.9 points better on a 0 to 24
disability scale. The number of adverse events was not significantly different between the people receiving NSAIDs and people receiving
placebo, but larger studies of longer duration would be needed to identify rare or delayed adverse events, important drug interactions
and adverse events occurring with prolonged use.
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Different types of NSAIDs did not show significantly different effects. Three of the 13 included studies compared two different types
of NSAIDs and none found any differences.
NSAIDs were also compared to other drug types: paracetamol, tramadol and pregabalin. There were no differences found between
NSAIDs and paracetamol and pregabalin in either effect or adverse events. A single study comparing celecoxib with tramadol showed
a better global improvement in peoples using celecoxib.
One trial compared NSAIDs with ’home-based exercise’. Regarding disability, people who did exercise improved more than people
receiving NSAIDs, but pain scores were not statistically different.
Quality of the evidence
There was low quality evidence that NSAIDs are slightly more effective than placebo in chronic low back pain. The magnitude of the
difference was small, and when we only accounted for trials of higher quality, these differences reduced.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
NSAIDs for people with chronic low back pain compared to placebo
Participant or population: people with chronic low back pain
Settings: General pract ice and outpat ient clinic
Intervention: NSAIDs
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Control NSAIDs
Change in pain intensity
from baseline
100 mm VAS
Follow-up: 9 to 112 days
Not est imable The mean change in pain
intensity f rom baseline in
the intervent ion groups was
6.97 lower
(10.74 to 3.19 lower)
- 1354
(6 trials)
⊕⊕©©
low1,2,3
Change in disability from
baseline
RDQ 0 to 24
Follow-up: 4 to 16 weeks
Not est imable The mean change in disabil-
ity f rom baseline in the in-
tervent ion groups was
0.85 lower
(1.30 to 0.40 lower)
- 1161
(4 trials)
⊕⊕©©
low3,4,5
Proportion of partici-
pants experiencing ad-
verse events
Follow-up: 9 to 112 days
Study population RR 1.04
(0.92 to 1.17)
1354
(6 trials)
⊕⊕©©
low1,2,3
410 per 1000 427 per 1000
(378 to 480)
M oderate
477 per 1000 496 per 1000
(439 to 558)
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Sensitiv-
ity analysis: change in pain
intensity from baseline
100 mm VAS
Follow-up: 2 to 16 weeks
Not est imable The mean sensit ivity analy-
sis change in pain intensity
f rom baseline. in the inter-
vent ion groups was
5.03 lower
(10.37 lower to 0.32 higher)
- 728
(3 trials)
⊕⊕⊕©
moderate6
Sen-
sitivity analysis: change in
disability from baseline
RDQ 0 to 24
Follow-up: 6 to 16 weeks
Not est imable The mean sensit ivity analy-
sis change in disability f rom
baseline in the intervent ion
groups was
0.41 lower
(1.04 lower to 0.23 higher)
- 654
(2 trials)
⊕⊕⊕©
moderate7
Sensitivity analysis: pro-
portion of participants ex-
periencing adverse events.
Follow-up ≤ 16 weeks
Follow-up: 2 to 16 weeks
Study population RR 0.93
(0.81 to 1.07)
728
(3 trials)
⊕⊕⊕©
moderate6
536 per 1000 498 per 1000
(434 to 573)
M oderate
522 per 1000 485 per 1000
(423 to 559)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed
risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; RR: risk rat io; RDQ: Roland Morris Disability Quest ionnaire. VAS: Visual Analogue Scale
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
1Allocat ion concealment was uncertain in most included trials, and randomizat ion was uncertain in half of the included trials,
therefore select ion bias is likely. Five out of six trials had high drop-out rates, so attrit ion bias is likely, one level downgrade.
2Two out of six trials allowed co-intervent ions. Two trials included a ’f lare design’, one level downgrade.
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3See funnel plot: we could not detect publicat ion bias, no downgrade.
4Allocat ion concealment was uncertain in most included trials. All f our trials had high drop-out rates, so attrit ion bias is highly
likely, one level downgrade.
5One included trial allowed co-intervent ions. One trial included a ’f lare design’, one level downgrade.
6Allocat ion concealment and randomizat ion were uncertain in all included trials, therefore select ion bias is likely. Two out of
three included trials had high drop-out rates, so attrit ion bias is likely, one level downgrade.
7Allocat ion concealment and randomizat ion was uncertain in both trials, therefore select ion bias is likely. Both trials had high
drop-out rates, so attrit ion bias is likely, one level downgrade.
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B A C K G R O U N D
Description of the condition
Low back pain is a major health problem and has a reported life-
time prevalence of up to 84% (Cassidy 1998;Walker 2000). More
than one quarter of North Americans have reported to have ex-
perienced low back pain within the previous three months (Deyo
2006) and low back pain is a leading cause of years lived with
disability (Vos 2012). In the first three months, a large proportion
of patients will recover, but most people still experience pain af-
ter one year (Itz 2013). Chronic low back pain is associated with
more disability and these people make a great demand on the
healthcare system (Webb 2003). Also, low back pain is the most
common type of pain in people experiencing any chronic pain
(Müller-Schwefe 2011a) and people with chronic low back pain
use healthcare more compared to people with acute low back pain
(Müller-Schwefe 2011b). For treatment, guidelines recommend
staying active and exercising, if necessary with the use of anal-
gesics. Non-steroidal anti-inflammatory drugs (NSAIDs) are one
of the most frequently used analgesics in low back pain manage-
ment (Gore 2012; Piccoliori 2013). People with acute low back
pain can receive NSAIDs for their pain, and short term NSAID
use is recommended for pain relief in people with chronic back
pain (Airaksinen 2006).
Description of the intervention
Most guidelines on treatment of low back pain recommend using
paracetamol as first choice, followed by NSAIDs if paracetamol is
insufficient (Koes 2010). NSAIDs are widely available in several
types and brands and both over-the-counter and on prescription.
NSAID treatment is based on the analgesic and anti-inflamma-
tory mechanisms of the drug, but is also associated with adverse
events, such as gastro-intestinal (Sostres 2013;Wehling 2014) and
cardiovascular events (Kearney 2006).
How the intervention might work
Cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) are
key enzymes in prostaglandin synthesis, which contribute to in-
flammation, pain and fever. NSAIDs inhibit the COX enzymes
and can therefore inhibit the production of prostaglandins. Con-
sequently this can reduce inflammation, pain and fever. COX-1
produces prostaglandins that also support platelets and protect the
stomach lining. It also helps to maintain kidney function. COX-
1 inhibition can raise the risk of renal insufficiency and gastro-
intestinal adverse events, such as gastritis or stomach bleeding.
There are two types of NSAIDs: non-selective NSAIDs, which
inhibit both COX-1 and COX-2 enzymes, and selective NSAIDs,
which inhibit only the COX-2 enzyme. Both selective and non-
selective NSAIDs are available for pain treatment, and the choice
of NSAID is mostly based on the different possible known adverse
events, convenience of use, and cost.
Non-selective or traditional NSAIDs have a higher risk compared
to selective NSAIDs regarding gastro-intestinal adverse events
(Sostres 2013) due to the inhibition of both COX enzymes.
However, aside from these gastro-intestinal benefits of selective
NSAIDs, there is a known cardiovascular risk from use of these
NSAID types. Cardiovascular risks are also present in non-selec-
tive NSAIDs and should be taken into account when prescribing
any NSAIDs (CNT Collaboration 2013; Trelle 2011).
Why it is important to do this review
This Cochrane review is one of a series of Cochrane reviews of
NSAIDs for people with low back pain and is an update of a
Cochrane review first published in 2008 (Roelofs 2008). The orig-
inal review consisted of 65 randomized controlled trials (RCTs);
for this update we decided to create a series of Cochrane reviews
regarding NSAID use for acute back pain, chronic back pain and
sciatica. Also, efficacy of treatment with NSAIDs can differ among
these different types of back pain. This Cochrane review focuses
on NSAIDs for treating people with chronic low back pain.
O B J E C T I V E S
To determine if NSAIDs are more efficacious than various com-
parison treatments for non-specific chronic low back pain and if
so, which type of NSAID is most efficacious.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included double-blinded and single-blinded randomized con-
trolled trials (RCTs). We only included English, German orDutch
trials, as we had stated in the original Cochrane protocol.
Types of participants
We included participants aged 18 years or older, who were treated
for non-specific chronic low back pain. We defined chronic low
back pain as pain for at least 12 weeks. If the trial did not describe
the duration of back pain, but labeled back pain as chronic, we
included the trial. If a trial included mixed populations of acute,
sub-acute or chronic low back pain, we only included these trials if
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they presented chronic low back pain data separately.We excluded
participants with sciatica or with specific low back pain caused
by pathological entities, such as infection, neoplasm, metastasis,
osteoporosis, rheumatoid arthritis or fractures.
Types of interventions
We included RCTs that assessed one or more types of NSAIDs.
We permitted additional interventions if there was a contrast for
NSAIDs in the trial. For example, we included trials that compared
NSAIDs plus muscle relaxants versus muscle relaxants alone, but
excluded trials that comparedNSAIDsplusmuscle relaxants versus
paracetamol.
We excluded trials that usedNSAIDswhich are no longer available
on the market, such as rofecoxib.
Types of outcome measures
Primary outcomes
Primary outcome measures were:
• pain intensity (e.g. visual analogue scale (VAS) or
Numerical Rating Scale (NRS))
• global measure (e.g. overall improvement, proportion of
participants that recover)
• back pain-specific functional status (e.g. Roland Disability
Questionnaire, Oswestry Scale)
• return to work (e.g. return to work status, number of days
off work)
• adverse events (proportion of participants experiencing
adverse events)
Secondary outcomes
Secondary outcome measures were physiological outcomes (e.g.
range of motion, spinal flexibility, degrees of straight leg raising or
muscle strength) and generic functional status (e.g. Short Form 36
(SF-36), NottinghamHealth Profile, Sickness Impact Profile).We
also considered other symptoms, such as health care consumption.
Search methods for identification of studies
Electronic searches
We identified RCTs for inclusion by searching the following
databases up to 24 June 2015:
• Cochrane Central Register of Controlled Trials
(CENTRAL, the Cochrane Library, Issue 5 of 12, May 2015)
• MEDLINE (OvidSP, 1946 to June Week 2 2015)
• MEDLINE In-Process & Other Non-Indexed Citations
(OvidSP, June 23, 2015)
• EMBASE (OvidSP, 1980 to 2015 Week 25)
• ClinicalTrials.gov
• World Health Organization International Clinical Trials
Registry Platform (WHO ICTRP)
• PubMed
For this update, we conducted the literature searches annually be-
tween May 2012 and 24 June 2015. We added the trial registers
(clinicaltrials.gov and WHO ICTRP) in 2013, MEDLINE In-
Process & Other Non-Indexed Citations in 2014 and PubMed in
2015 to identify studies not in MEDLINE using the strategy rec-
ommended by Duffy 2014. We have presented the search strate-
gies in Appendix 1, Appendix 2, Appendix 3, Appendix 4 and
Appendix 5.
A research librarian from the Cochrane Back and Neck Review
Group devised and performed these searches according to the
guidelines of theCochrane Back andNeckReview Group (Furlan
2009).
Searching other resources
After the electronic search, we screened systematic reviews regard-
ing NSAIDs for chronic low back pain. We included articles that
we had included in the previous version of this Cochrane review
(Roelofs 2008).
Data collection and analysis
Selection of studies
Two review authors (BK and PR, or PR and WE) independently
screened all search results. We excluded clearly ineligible studies
based on title and abstract. We retrieved full-text articles of all
remaining studies and two review authors screened these articles
independently for inclusion. We resolved any disagreements re-
garding inclusion by consensus between the review authors.
Data extraction and management
One review author, WE, extracted the data, and a second review
author, PR, checked the extracted data. The review authors ex-
tracted data on type and dose of NSAIDs, type of reference treat-
ment, follow-up time, duration of current symptoms and the out-
comes described above. If data were unavailable for data extraction
due to use of a different format, we contacted the trial authors
for further information. We resolved any disagreements through
consensus between all review authors.
Assessment of risk of bias in included studies
Two review authors (WE andPR) independently evaluated the risk
of bias of all included trials, using the criteria list recommended by
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the Cochrane Back Review Group (Furlan 2009) and described in
Appendix 6. We scored each of the criteria as either ’low’, ’high’
or ’unclear’ risk. If we scored the criteria as unclear, we did not
contact the trial authors for further information. We resolved any
disagreements by consensus and consulted a third review author
if disagreements persisted.
Measures of treatment effect
The primary outcome, pain intensity, is measured with the VAS
or NRS on a scale from 0 to 100 and 0 to 10 respectively. Global
improvement is measured by the proportion of participants that
recovered.Disability ismeasured on different disability scales, (e.g.
RolandMorrisDisabilityQuestionnaire (RDQ)on a0 to24 scale).
Adverse events are measured by the proportion of participants
experiencing any adverse event.
Dealing with missing data
We did not include data in this review that were not reported in
the article and that we considered missing. If trials showed data
in graphs instead of describing data in the text but were shown in
graphs, we collected data from the graphs.
Assessment of heterogeneity
We assessed clinical heterogeneity for all included RCTs that re-
ported similar outcomes. We judged the included trials based on
setting, participants and intervention. If trials were clinically het-
erogeneous, we did not pool them. We assessed statistical hetero-
geneity using the Chi² test and I² statistic. If I² statistic values
were greater than 50%, substantial heterogeneity could be present
(Higgins 2011) and we pooled data using a random-effects model.
When we suspected no, low or moderate heterogeneity, we used a
fixed-effect model.
Assessment of reporting biases
We used funnel plots to investigate reporting bias when we in-
cluded at least four trials in a particular comparison.
Data synthesis
We analysed dichotomous outcomes by calculating the relative risk
(RR). We analysed continuous outcomes by calculating the mean
difference (MD) when the same instrument was used to measure
outcomes, or the standardized mean difference (SMD) when dif-
ferent instruments were used to measure the outcomes. We ex-
pressed uncertainty with 95% confidence intervals (95%CIs).We
performed a meta-analysis if studies were clinically homogeneous
(comparable population, intervention and outcomes among tri-
als) using a fixed-effect model unless there was significant statisti-
cal heterogeneity, in which case we used a random-effects model.
We used the I² and chi² test to assess statistical heterogeneity as
suggested in the Cochrane handbook (Higgins 2011). If meta-
analysis was not possible, we described the results from clinically
comparable trials in the review text.
We assessed the overall quality of the evidence for each outcome
using the GRADE approach, as recommended in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011)
and adapted in the updated CBRG method guidelines (Furlan
2009). Five factors that may have decreased the quality of the ev-
idence were: study design and risk of bias, inconsistency of re-
sults, indirectness (not generalizable), imprecision (sparse data)
and other factors (e.g. reporting bias). We downgraded the quality
of the evidence for a specific outcome by one level according to
the performance of the studies against each of these five factors.
We assessed the overall quality of the evidence for each outcome
as:
• High quality evidence: there are consistent findings
among at least 75% of RCTs with low risk of bias, consistent,
direct and precise data and no known or suspected publication
biases. Further research is unlikely to change either the estimate
or our confidence in the results.
• Moderate quality evidence: one of the domains is not met.
Further research is likely to have an important impact on our
confidence in the estimate of effect and may change the estimate.
• Low quality evidence: two of the domains are not met.
Further research is very likely to have an important impact on
our confidence in the estimate of effect and is likely to change
the estimate.
• Very low quality evidence: three of the domains are not
met. We are very uncertain about the results.
• No evidence: we did not identify any RCTs that addressed
this outcome.
Subgroup analysis and investigation of heterogeneity
We performed subgroup analyses if both non-selective and selec-
tive NSAIDs were present.We split these results into non-selective
and selective NSAIDs.
Sensitivity analysis
We performed a sensitivity analysis on the comparison between
NSAIDs and placebo. We excluded trials at high risk of bias (less
than six positive items on the ’Risk of bias’ table) or trials with a
’flare design’ from this analysis. A trial with a ’flare design’ only
includes participants who previously used NSAIDs and reported
aggravated back complaints during a washout period.
R E S U L T S
Description of studies
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Results of the search
We identified a total of 3437 potential articles in the updated elec-
tronic search (Figure 1). After screening the titles and abstracts,
we assessed full-text articles and included 13 trials. Amongst these
were seven of the nine articles on chronic low back pain from
Roelofs 2008. Two trials reported on rofecoxib, which was with-
drawn from the market, and we excluded these trials from this
review (Chrubasik 2003; Katz 2003).
Figure 1. study flow diagram.
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Included studies
The sample size of the 13 included trials ranged from 28 to 1593
participants, with a total of 4807 included participants. Six trials
compared NSAIDs versus placebo (Allegrini 2009; Berry 1982;
Birbara 2003; Coats 2004; Katz 2011; Kivitz 2013). Three tri-
als compared two different types of NSAIDs (Driessens 1994;
Videman 1984; Zerbini 2005). One trial compared NSAIDs ver-
sus paracetamol (Hickey 1982), one trial compared NSAIDs ver-
sus tramadol (O’Donnell 2009) and one trial compared NSAIDs
versus pregabalin (Romanò 2009). One trial compared exercise
therapy versus NSAIDs (Shirado 2010).
Excluded studies
We have described the reasons for exclusion of studies in the
’Characteristics of excluded studies’ table.We excludedmost stud-
ies because it was unclear whether participants had chronic low
back pain.
Risk of bias in included studies
We have presented the ’Risk of bias’ assessment in Figure 2 and
Figure 3. Ten of the 13 studies were considered having a low risk
of bias. (Berry 1982; Birbara 2003; Coats 2004; Driessens 1994;
Hickey 1982; Katz 2011; Kivitz 2013; O’Donnell 2009; Shirado
2010; Zerbini 2005).
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each ’Risk of bias’ item for each
included trial.
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Figure 3. ’Risk of bias’ graph: review authors’ judgements about each ’Risk of bias’ item presented as
percentages across all included trials.
Allocation
Of the 13 included studies, six reported a randomization proce-
dure (Allegrini 2009; Birbara 2003; Coats 2004; Hickey 1982;
O’Donnell 2009; Shirado 2010). Of these six studies, only four
also adequately described concealment of treatment allocation
(Birbara 2003; Hickey 1982; O’Donnell 2009; Shirado 2010).
Most studies did not report the method of randomization or allo-
cation concealment and were scored as ’unclear’ on these items.
Blinding
Seven included trials reported blinding of patients, care providers
and outcome assessors (Berry 1982; Birbara 2003;Driessens 1994;
Hickey 1982; O’Donnell 2009; Videman 1984; Zerbini 2005).
The other six trials did not blind patients, care providers, or out-
come assessors or they did not report on blinding.
Incomplete outcome data
Six trials reported low drop out rates (Berry 1982; Hickey 1982;
Romanò 2009; Shirado 2010; Videman 1984; Zerbini 2005). The
seven other studies reported drop-out rates higher than 20% (
Allegrini 2009; Birbara 2003; Coats 2004; Driessens 1994; Katz
2011; Kivitz 2013; O’Donnell 2009).
Only three trials performed an intention to treat (ITT) analysis
(Coats 2004; Katz 2011; O’Donnell 2009).
Selective reporting
Only twoRCTswere registered in an accessible clinical trial registry
(Katz 2011; Kivitz 2013) and had low risk of reporting bias.
Other potential sources of bias
Most studies showed similarity of baseline characteristics; only
three RCTs did not report this (Allegrini 2009; Hickey 1982;
Videman 1984).
Regarding co-interventions, only paracetamol as rescue medica-
tion was allowed; other types of medication were not. All but two
trials avoided co-interventions (Berry 1982; Birbara 2003) and
one trial did not state anything about co-interventions (Shirado
2010).
Nine trials reported compliance, and five trials had acceptable
compliance (Allegrini 2009; Coats 2004; Katz 2011; Romanò
2009; Zerbini 2005). Four other trials had unacceptable com-
pliance (Berry 1982; Birbara 2003; Driessens 1994; O’Donnell
2009).
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Timing of outcome assessment was similar between the groups in
almost all included trials.
We created funnel plots to assess risk of publication bias and for
the analysis of NSAIDs versus placebo (Figure 4; Figure 5; Figure
6). We could not identify publication bias. We did not create any
funnel plots for other comparisons, since less than four RCTs were
available for this analysis.
Figure 4. Funnel plot of comparison: 1 NSAIDs versus placebo, outcome: 1.1 Change in pain intensity from
baseline on 100 mm VAS. Follow-up ≤ 12 weeks.
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Figure 5. Funnel plot of comparison: 1 NSAIDs versus placebo, outcome: 1.2 Change in disability from
baseline.
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Figure 6. Funnel plot of comparison: 1 NSAIDs versus placebo, outcome: 1.3 Proportion of patients
experiencing adverse events. Follow-up ≤ 16 weeks.
Half of the included trials reported a potential conflict of interest.
Three studies reported support from a pharmaceutical company
(Birbara 2003; Hickey 1982; Zerbini 2005) and the authors of
four RCTs had affiliations with a pharmaceutical company (Coats
2004; Katz 2011; Kivitz 2013; O’Donnell 2009). The remaining
six RCTs did not report any potential conflict of interest.
Effects of interventions
See: Summary of findings for the main comparison NSAIDs
for people with chronic low back pain
See: ’Summary of findings’ table 1.
Efficacy of NSAIDs compared to placebo
Six RCTs compared NSAIDs with placebo (Allegrini 2009; Berry
1982; Birbara 2003;Coats 2004;Katz 2011;Kivitz 2013).Median
follow-up was 56 days (IQR 13 to 91 days). Three of these trials
reported short-termoutcomes of fourweeks or less (Allegrini2009;
Berry 1982; Coats 2004). The other three trials had a duration
of follow-up of 12 or 16 weeks (Birbara 2003; Katz 2011; Kivitz
2013). Naproxen was the most common type of NSAID (Berry
1982; Katz 2011; Kivitz 2013), but piroxicam patch, etoricoxib
and valdecoxib were also compared to placebo.
All RCTs reported pain intensity on a 100 mm VAS or 11-point
numerical rating scale (NRS). The Chi² value for homogeneity
of the mean difference (MD) was 10.41 (P 0.06) and I² statis-
tic 52%, which suggests substantial statistical heterogeneity. This
might be due to different types of NSAIDs used in the trials and
we used a random-effects model to pool these data. The pooled
mean difference in pain intensity score from baseline was −6.97
(95% CI −10.74 to −3.19; Analysis 1.1), indicating a statisti-
cally significant effect in favour of participants receiving NSAIDs
compared to participants receiving placebo. The quality of this
evidence was low (Summary of findings for themain comparison).
When we split results into selective and non-selective NSAIDs
versus placebo, there was still a substantial statistical heterogene-
ity among the trials considering non-selective NSAIDs, although
three out of four RCTs used naproxen as trial medication. There
was statistical homogeneity among the trials on selective NSAIDs.
The effect of selective NSAIDs was somewhat larger and the effect
of non-selective NSAIDs was smaller.
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Four RCTs compared NSAIDs with placebo, with disability as
outcome measure, measured with the Roland Morris Disability
Questionnaire (RDQ) (Birbara 2003; Coats 2004; Katz 2011;
Kivitz 2013) on a 0 to 24 scale. Median follow-up was 84 days
(IQR 42 to 105 days). The Chi² value for homogeneity of the
mean difference (MD) was 5.53 (P = 0.14) and the I² statistic was
46%, indicating moderate statistical heterogeneity among these
trials. The pooled mean difference in disability from baseline was
−0.85 (95% CI −1.30 to −0.40; Analysis 1.2). The quality of
this evidence was low (’Summary of findings’ table 1).
All trials also reported adverse events. The Chi² value for homo-
geneity of the RR for adverse events in all RCTs was 6.22 (P =
0.28) and the I² statistic value was 20%, indicating no statistical
heterogeneity among the RCTs. The pooled RR for adverse events
was 1.04 (95% CI 0.92 to 1.17; Analysis 1.3), indicating that ad-
verse events were not statistically significant more present in par-
ticipants using NSAIDs compared to placebo. Using the GRADE
approach, we assessed the quality of evidence of these trials as
low (’Summary of findings’ table 1). Results did not change when
we specified NSAIDs into selective and non-selective NSAIDs,
although adverse events in selective NSAIDs showed a trend in
favour of placebo. However, RCTs have low power in detecting
uncommon and delayed adverse events. The sample sizes of most
included trials were relatively small and duration of follow-up
was relatively short. It is possible that not all adverse events had
emerged, especially since most important adverse events are rare
and can take weeks or months to present. Therefore, we cannot
make firm statements about the difference in occurrence of adverse
events between different NSAID types.
Of the trials that compared NSAIDs with placebo, we considered
three trials at high risk of bias (Allegrini 2009; Birbara 2003; Coats
2004). The latter two trials used a ’flare design’. We performed a
sensitivity analysis using the three RCTs which were at low risk of
bias (Berry 1982; Katz 2011; Kivitz 2013). The difference between
NSAIDs and placebo on pain intensity score (on 0 to 100 mm
VAS) and the disability (measured with RDQ 0 to 24) became
smaller and was no longer statistically significant; the difference
in pain intensity score between NSAIDs and placebo was −5.03
(95% CI −10.37 to 0.32; Analysis 1.4) and for disability was
−0.41 (95% CI −1.04 to 0.23; Analysis 1.5). We assessed the
quality of evidence as moderate (’Summary of findings’ table 1).
Efficacy of selective versus non-selective NSAIDs and
non-selective versus non-selective NSAIDs
Two small RCTs compared two types of non-selective NSAIDs
(Driessens 1994; Videman 1984). Driessens 1994 compared
ibuprofen (1600 mg/day) and diclofenac (100 mg/day) for two
weeks, Videman 1984 compared piroxicam (20 mg/day) and in-
domethacin (75mg/day) for six weeks. Both trials found no signif-
icant difference between the two types of non-selective NSAIDs.
The number of adverse events in Driessens 1994 was statistically
significant higher in the diclofenac group. In Videman 1984 there
was no statistically significant difference in experienced adverse
events between the two trial groups. One other RCT, Zerbini
2005, compared a non-selective NSAID with a COX-2 inhibitor
(diclofenac 150 mg/day versus etoricoxib 60 mg/day for four
weeks). This trial included 440 participants in the analysis and
found no significant difference in change in pain intensity from
baseline between the non-selective NSAIDs and COX-2 inhibitor.
The trial also did not find any differences in adverse events in gen-
eral and specific gastrointestinal adverse events between the two
trial groups.
Efficacy of NSAIDs versus other drugs
NSAIDs compared to other drug types are shown in Analysis
2.1 and Analysis 2.2. We did not pool these RCTs because the
trials used different types of medication as comparison. Hickey
1982, which had with 30 participants, compared NSAIDs (diflu-
nisal 1000 mg/day) with paracetamol (4000 mg/day). In this trial,
NSAIDs were not significantly better than paracetamol and ad-
verse events were not significantly more present in patients using
NSAIDs compared to the other studied drugs.
O’Donnell 2009 included 1593 participants and compared
NSAIDs (celecoxib 400 mg/day) with tramadol (200 mg/day) for
six weeks. Results of global improvement (RR 1.26, 95% CI 1.16
to 1.38) and adverse events (RR 0.83, 95% CI 0.75 to 0.91) after
six weeks both favoured celecoxib.
Romanò 2009 compared celecoxib with pregabalin and scored
change in pain intensity from baseline to four weeks on a VAS
score. There was no significant difference between the two trial
groups and adverse eventswere similar in number in both celecoxib
and pregabalin trial groups.
Efficacy of NSAIDs versus non-drug treatment
One RCT, Shirado 2010, compared NSAIDs with ’home-based
exercise’. Improvement in functional status between baseline and
eight weeks was significantly better in exercise participants then
participants receivingNSAIDs, but there was no difference in pain
intensity.
D I S C U S S I O N
Summary of main results
In this Cochrane review we included 13 RCTs that assessed
NSAID efficacy for the management of chronic low back pain.
Six trials comparing NSAIDs with placebo showed low quality ev-
idence that NSAIDs are more effective than placebo, with a mean
difference in pain intensity score from baseline of -6.97 (95% CI
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−10.74 to−3.19) on a 0 to 100 visual analogue scale (VAS) with
a median follow-up of 56 days (IQR 13 to 91 days). There is also
low quality evidence that NSAIDs are more effective than placebo
on disability, with a mean difference from baseline of−0.85 (95%
CI−1.30 to−0.40) on a scale from 0 to 24 with a median follow-
up of 84 days (IQR 42 to 105 days). When only trials with low
risk of bias were included in the analysis, the difference between
NSAIDs and placebo was no longer significant. Adverse events
were not significantly more present in theNSAIDs or placebo trial
group, but this could be because we only included RCTs in this
review, or the short duration of use and the short follow-up period
in most included trials.
Studies comparing non-selective versus selective NSAIDs or com-
paring different types of non-selective NSAIDs were also limited
available. All three included RCTs showed no significant effect
between the different NSAID types.
Whether NSAIDs are more effective than other drugs or non-
drug therapies for people with chronic low back pain remains
unclear. A limited number of trials comparedNSAIDs versus other
drug treatments and all trials included different kind of drugs
as comparator. One large RCT compared celecoxib to tramadol.
Results of global improvement and adverse events were both in
favour of celecoxib after six weeks.
Overall completeness and applicability of
evidence
In this Cochrane review we used strict inclusion criteria regarding
the duration of back pain, meaning that we only included trials
that reported results on people with chronic low back pain. This
means that fewer trials met the inclusion criteria of this Cochrane
review, but it makes the review results more distinct for people
with non-specific chronic low back pain.
Two included trials used a ’flare design’. These trials included par-
ticipants who responded well to NSAIDs when they showed a
worsening in back pain during a wash-out period. As these partic-
ipants already responded well to NSAIDs, these trials are likely to
have overestimated the effect of NSAIDs. It may also reduce the
external validity since this is a select group of participants. When
we excluded these RCTs from the analysis together with one other
trial with a high risk of bias, the results changed. The magnitude
of effect of NSAIDs became smaller and the difference was not
statistically significant anymore.
Some included trials operationalized outcomes differently and not
all trials included disability as outcome.None of the included trials
mentioned return to work or other work outcomes, although this
might be an important outcome in patients with chronic low back
pain.
Almost all included RCTs mentioned adverse events. Most trials
reported the overall number of adverse events, and some trials also
mentioned specific gastrointestinal adverse events. Cardiovascular
adverse events are rarely mentioned. However, these trials were
powered to investigate treatment effects of the primary outcomes.
As most important adverse events are rare and can take weeks or
months to evolve, it is likely that sample sizes of these trials were
too small and follow-upperiods too short to draw clear conclusions
from these trials regarding the risks for gastrointestinal and other
adverse events of NSAIDs.
Quality of the evidence
Three includedRCTswere considered high risk of bias. Even in the
10 other RCTs with low risk of bias other methodological short-
comings were present, such as no clear description of the random-
ization procedure, high drop-out rates and low or unclear com-
pliance in the trial groups. Uncertain or low compliance makes it
difficult to interpret the measured effect in the study and can both
under- and overestimate the results found. The level of evidence,
which we assessed using the GRADE approach, was low due to
similar issues. The most common reasons for downgrading evi-
dence were ’risk of bias’ and ’imprecision’ for the included trials.
Most trials had a follow-up period of at least four weeks, and only
three trials had follow-up periods of less than four weeks (ranging
from nine days to two weeks). NSAIDs are usually used for a
short period of time. This short follow up period might not have
consequences on our results, since effects are expected shortly after
the start of the NSAIDs. Although it is difficult due to this short
follow-up period to assess adverse events.
Included RCTs had different trial population sizes; four trials in-
cluded less than 50 participants and may lack statistical power to
detect differences in effects. Pooling may overcome this problem.
However, themost important question is whether the effect is clin-
ically relevant. The main finding that NSAIDs are more effective
than placebo on pain intensity was based on a meta-analysis that
showed a mean difference of 3.30 on a 0 to 100 scale. Although
statistically significant, one could argue that this effect is too small
to be clinically relevant.
A sensitivity analysis with a moderate quality of evidence showed
that the positive effect of NSAIDs compared to placebo was re-
duced and no longer statistically significant whenwe only included
RCTs in the analysis that were of low risk of bias.
Potential biases in the review process
We only included trials published in English, German or Dutch,
which could have led to the exclusion of trials published in other
languages from this Cochrane review. Reports on language bias
show conflicting results (Higgins 2011; Jüni 2002; Moher 2003).
It is not to be expected that inclusion of articles written in other
languages will change the results in this review, especially since
there seems to be a shift in publishing more articles in English and
less frequent in other languages (Galandi 2006; Higgins 2011).
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Only one review author extracted data and the second review au-
thor checked the extracted data. This could have led to a higher
risk of error in data extraction.
Different types and chemical entities of NSAIDs are available,
which makes it difficult to compare different NSAIDs. Regard-
ing the comparison of NSAIDs versus placebo, we included both
selective and non-selective NSAIDs. An analysis of two separate
comparisons showed no differences in directions of the findings
when we compared selective and non-selective NSAIDs separately
with placebo.
Publication bias may have occurred, but this was difficult to as-
sess due to the limited number of included trials. In particular the
comparisons of different NSAID types or NSAIDs compared to
other types of drugs we could not examine publication bias using
a funnel plot. Half of the included trials were supported by or
included authors from pharmaceutical companies. Clinical trials
sponsored by pharmaceutical companies are less likely to be pub-
lished and are more likely to have outcomes in favour of the spon-
sor (Lexchin 2003), which could have caused publication bias.
Even when publication bias would have occurred, this will not
change the found results. The found effect is already very small
and not clinically relevant.
Agreements and disagreements with other
studies or reviews
In the previous version of this Cochrane review, Roelofs 2008,
we studied NSAIDs for people with sciatica, acute and chronic
low back pain based on literature published from September 1998
to June 2007. These trials found a change in pain intensity in
favour of NSAIDs compared to placebo. In this review update
we found similar results, but the magnitude of the results in our
review was smaller than found in Roelofs 2008. Adverse events
were statistically more present in the NSAID group in Roelofs
2008, but we did not find a statistically significant difference in
our review. Most trials included in this Cochrane review had a
small sample size or short-time follow-up, or both, and were not
suited to evaluate adverse events. A large meta-analysis on adverse
events inRCTs (CNT Collaboration 2013) and observational data
(Castellsague 2012) showed that adverse events are more present
in participants using NSAIDs compared to placebo.
After 2008, several systematic reviews were published regarding
NSAIDs as a therapeutic option in treating people with chronic
low back pain. Pain scores between NSAIDs and placebo were
often reported. In 2013, a review on NSAIDs showed that COX-
2 selective NSAIDs were significantly more effective in reducing
VAS score and disabilitymeasuredwith RDQ (Chung 2013). Four
studies were included in Chung’s analysis, of which we did not
include two in this Cochrane review. We excluded one trial, Pallay
2004, from the previous version of this review because it is ad-
ditional information to an earlier reported study that was already
included in the review (Birbara 2003). Including both would lead
to double counting. The other study, Katz 2003, reported on ro-
fecoxib and was excluded from this review because it was with-
drawn from the market. Kuijpers 2011 found similar results to
Chung 2013 and concluded that there is low quality evidence that
NSAIDs are more effective than placebo. This is comparable to
findings in this Cochrane review. Chung 2013 also assessed dis-
ability and results were comparable to our findings..
Chung 2013 also evaluated selective and non-selective NSAIDs
and found no differences in efficacy between these two groups.
Two studies were analysed in the review; one of those was also
examined in this review and found the same results. We excluded
the other study used in Chung 2013 from this Cochrane review
because it included rofecoxib.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
For people with chronic lowback pain there is low quality evidence
that NSAIDs are slightly better in reducing pain and disability
than placebo, but the effect is very small and possibly not clinically
relevant. The low risk of bias studies showed no significant differ-
ence betweenNSAIDs and placebo. It is unclear whether NSAIDs
are more effective than other drugs and there is no evidence to
show that one NSAID type is more effective than other types.
Implications for research
The quality of evidence for NSAIDs compared to placebo in peo-
ple with chronic low back pain is, at best, moderate. When stud-
ies are of higher quality, effects of NSAIDs become smaller or
disappear. It is questionable whether or not additional research
will change these findings and the estimate of effect. Especially
since the observed differences in this study between NSAIDs and
placebo are small and possibly not clinically relevant. In studies
with flare designs, some participants respond toNSAID treatment.
Therefore, it might be worthwhile to look into subgroups finding
participants who are likely to respond well to NSAIDs.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Allegrini 2009
Methods RCT
Participants 180 participants, 102 women and 78 men; mean age 51 years (range 19 to 78 years)
Inclusion: symptomatic lumbar osteoarthritis with daily pain during daily activities de-
fined as a score as 40 mm on a 100 mm VAS
Exclusion: participants with known hypersensitivity or allergy to piroxicam or to other
NSAIDs; participants using topical medications to the painful region and the use of
steroids by any route within 7 days before inclusion
Interventions NSAID (i): piroxicam patch 14mg/day, 8 consecutive days (N = 60)
NSAID (ii): piroxicam 1% cream, 1.4g/day, 8 consecutive days (N = 60)
Reference treatment (iii): placebo patch, 8 consecutive days (N = 60)
Outcomes Responder (reduction of pain score of at least 30%) rate to the administered treatment
after 9 days: (i) 60%, (ii) 62% and (iii) 34%
Adverse events: (i) 5 participants; (ii) 3 participants; (iii) 3 participants
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer randomized
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding (performance bias and detection
bias): All outcomes - Patients
All outcomes
Unclear risk Not mentioned
Blinding (performance bias and detection
bias): All outcomes - Care providers
All outcomes
Unclear risk Not mentioned
Blinding (performance bias and detection
bias): All outcomes - Outcome assessors
All outcomes
Unclear risk Not mentioned
Incomplete outcome data (attrition bias):
All outcomes - Drop-outs
All outcomes
High risk Each group had a drop out rate of > 20%
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Allegrini 2009 (Continued)
Incomplete outcome data (attrition bias):
All outcomes - ITT analysis
All outcomes
Unclear risk Not mentioned
Selective reporting (reporting bias) Unclear risk No protocol
Similarity of baseline characteristics Unclear risk No table with baseline characteristics
Co-interventions avoided or similar Low risk Rescue medication: paracetamol, up to 1.5 g per day allowed
Compliance acceptable Low risk All included participants were compliant
Timing outcome assessments similar Low risk Timing was similar
Berry 1982
Methods RCT, double blind, double-dummy, cross-over
Participants 37 participants, 24 women and 13 men; mean age 55 years (range 32 to 79); median
disease duration of 3 years
Inclusion: adult participants with chronic back pain (≥ 3 months) due to spondylosis,
degenerative spinal disease, sciatica or pain of nonspecific cause
Exclusion: pain due to malignant disorders, infective diseases, spondylolisthesis, an al-
kaline phosphatase level outside normal limits or an ESR > 25 mm/hour
Interventions NSAID (i): naproxen sodium 1100 mg/day, 14 days (N = 37 in cross-over design)
NSAID (ii): diflunisal 1000 mg/day, 14 days (N = 37 in cross-over design)
Reference treatment (iii): Placebo of dummy naproxen sodium capsules and diflunisal
tablets (N = 37 in cross-over design)
Outcomes Global pain, night pain, pain on movement and pain on standing assessed on vertical
10 cm VAS
Reduction of pain on (i), an increase of pain (iii), and no significant change on (ii)
Adverse events: (i) 18 participants; (ii) 16 participants; (iii) 18 participants
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomization procedure not mentioned
Allocation concealment (selection bias) Unclear risk Allocation procedure not mentioned
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Berry 1982 (Continued)
Blinding (performance bias and detection
bias): All outcomes - Patients
All outcomes
Low risk Patients were blinded
Blinding (performance bias and detection
bias): All outcomes - Care providers
All outcomes
Low risk Care providers were blinded
Blinding (performance bias and detection
bias): All outcomes - Outcome assessors
All outcomes
Low risk Outcome assessors were blinded
Incomplete outcome data (attrition bias):
All outcomes - Drop-outs
All outcomes
Low risk There was < 20% drop out
Incomplete outcome data (attrition bias):
All outcomes - ITT analysis
All outcomes
Unclear risk Unclear whether or not all participants
were analysed
Selective reporting (reporting bias) Unclear risk No protocol
Similarity of baseline characteristics Low risk Cross-over design
Co-interventions avoided or similar High risk Corsets, braces, physiotherapy and parac-
etamol were permitted as long as they were
started before entry to the study and con-
tinued unchanged for the trial duration
Compliance acceptable High risk 14 drug discontinuations in 37 people
Timing outcome assessments similar Low risk Timing was similar
Birbara 2003
Methods RCT, double blind
Participants 319 participants, 190 women and 124 men; mean age 52 years
Inclusion: participants 18 to 75 years, low back pain≥ 3months, at least the past 30 days
user of NSAID or acetaminophen. Pain without radiation to an extremity and without
neurological signs or with radiation but not below the knee; After wash out period: ≥
40 mm on low back intensity scale, increase of 10 mm and worsening of patient global
assessment of disease status by ≥ 1 point compared to first screening visit
Exclusion: low back pain due to malignancy, inflammatory disease, osteoporosis, fi-
bromyalgia, ochronosis, vertebral fracture, infection, juvenile scoliosis or congenital mal-
formation. Surgery in the past 6months, symptomatic depression, drugs or alcohol abuse
within the past 5 years, opioid usemore than 4 days in the previous month, corticosteroid
injections in the previous 3 months
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Birbara 2003 (Continued)
Interventions NSAID (i): etoricoxib 60 mg/day, 12 weeks (N = 103)
NSAID (ii): etoricoxib 90 mg/day, 12 weeks (N = 107)
Reference treatment (iii): placebo (N = 109)
Outcomes Mean difference (95% CI) pain intensity scale (100 mm VAS) at 12 weeks: (i versus iii)
−10.45 (−16.77 to −4.14); (ii versus iii) −7.5 (−13.71 to −1.28)
Mean difference (95% CI) LBP bothersomeness (4-point Likert scale) at 12 weeks: (i
versus iii) −0.38 (−0.62 to −0.14); (ii versus iii) −0.33 (−0.57 to −0.09)
Mean difference (95% CI) RDQ (0 to 24 point scale) over 12 weeks; (i versus iii) −2.
42 (−3.87 to −0.98); (ii versus iii) −2.06 (−3.46 to −0.65)
Adverse events: (i) 60 participants (14 withdrew), (ii) 56 participants (17 withdrew) (iii)
51 participants (10 withdrew)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer randomized
Allocation concealment (selection bias) Low risk Computer random allocation schedule
Blinding (performance bias and detection
bias): All outcomes - Patients
All outcomes
Low risk Patients were blinded
Blinding (performance bias and detection
bias): All outcomes - Care providers
All outcomes
Low risk Care providers were blinded
Blinding (performance bias and detection
bias): All outcomes - Outcome assessors
All outcomes
Low risk Outcome assessors were blinded
Incomplete outcome data (attrition bias):
All outcomes - Drop-outs
All outcomes
High risk High drop-out rates, 33%, 28%, 41%
Incomplete outcome data (attrition bias):
All outcomes - ITT analysis
All outcomes
High risk No ITT analysis
Selective reporting (reporting bias) Unclear risk No protocol
Similarity of baseline characteristics Low risk Basline characteristics similar
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Birbara 2003 (Continued)
Co-interventions avoided or similar High risk Muscle relaxants, physical therapy, and chiropractic or alterna-
tive therapy (such as acupuncture) were permitted, if their use
was stable for the month preceding the screening visit and was
expected to remain stable for the trial duration
Compliance acceptable High risk Discontinuation in 6%, 11% and 26%
Timing outcome assessments similar Low risk Timing was similar
Coats 2004
Methods RCT, double-blind; ’flare’ design
Participants 293 participants, 166 women, 127 men; mean age 48.7 years
Inclusion: participants ≥ 18 years with low back pain ≥ 3 months requiring regular use
of analgesic medication. Flare criteria after washout period
Exclusion: low back pain of neurologic aetiology or as the result of major trauma; surgical
interventions for low back pain < 4 weeks prior to study entry; participants who had
received corticosteroids or opioids
< 90 days prior to the first dose of study medication; secondary cause of low back pain;
pending workers’ compensation claims; pregnancy or breastfeeding
Interventions NSAID (i): valdecoxib 40 mg/day, 4 weeks (N = 148)
Reference treatment (ii): placebo, 4 weeks (N = 143)
Outcomes Mean change score on pain intensity scale (100 mm VAS) at 1 and 4 weeks: (i) 29.2 mm
and 41.9 mm; (ii) 17.7 mm and 31.1 mm; (i versus ii) all P < 0.001
Adverse events: (i) 52 participants (1 withdrew); (ii) 35 participants (3 withdrew)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly assigned using a computer generated list
of random numbers
Allocation concealment (selection bias) Unclear risk Procedure is not described
Blinding (performance bias and detection
bias): All outcomes - Patients
All outcomes
Low risk Patients were blinded
Blinding (performance bias and detection
bias): All outcomes - Care providers
All outcomes
Unclear risk Care providers were not mentioned in blinding pro-
cedure
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Coats 2004 (Continued)
Blinding (performance bias and detection
bias): All outcomes - Outcome assessors
All outcomes
Low risk Outcome assessors were blinded
Incomplete outcome data (attrition bias):
All outcomes - Drop-outs
All outcomes
High risk In placebo group drop-out rate was 21%
Incomplete outcome data (attrition bias):
All outcomes - ITT analysis
All outcomes
Low risk Intention-to-treat (ITT) analysis was used
Selective reporting (reporting bias) Unclear risk No protocol
Similarity of baseline characteristics Low risk Baseline characteristics similar
Co-interventions avoided or similar Low risk Rescue medication: acetaminophen ≤ 2000 mg/d
for ≤ 3 consecutive days only in the first week,
thereafter participants requiring any additional res-
cuemedicationwere to be withdrawn from the study
Compliance acceptable Low risk 3 participants (2%) versus 1 participant (< 1%)
withdrew
Timing outcome assessments similar Low risk Timing similar
Driessens 1994
Methods RCT, double-blind, double-dummy
Participants 62 participants, 33 women, 29 men; mean age (SD) 52.6 (14.3)
Inclusion: hospital outpatients, chronic back pain for at least 4 weeks and required
NSAID treatment
Exclusion: acute or chronic infections, neoplasm or metastases, other severe intercurrent
systemic disease, sciatica, referred pain from other organs or believed to be of psychogenic
origin, treatment with local corticosteroid injection within 4 weeks of study commence-
ment, pregnancy, lactation, contraindications for NSAID therapy
Interventions NSAID (i): ibuprofen sustained-release 1600 mg, plus placebo, 14 days (N = 30)
NSAID (ii): diclofenac sustained-release 100 mg, plus placebo, 14 days (N = 32)
Outcomes Mean (SD) overall change in clinical condition compared to baseline on a 9-point scale:
(i) 6.0 (1.4) (ii) 5.3 (1.5)
Adverse events: (i) 4 participants, (ii) 16 participants (P = 0.002)
Notes
Risk of bias
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Driessens 1994 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomization procedure not described
Allocation concealment (selection bias) Unclear risk Allocation procedure not described
Blinding (performance bias and detection
bias): All outcomes - Patients
All outcomes
Low risk Patients were blinded
Blinding (performance bias and detection
bias): All outcomes - Care providers
All outcomes
Low risk Care providers were blinded
Blinding (performance bias and detection
bias): All outcomes - Outcome assessors
All outcomes
Low risk Outcome assessors were blinded
Incomplete outcome data (attrition bias):
All outcomes - Drop-outs
All outcomes
High risk 25% of the participants in the diclofenac
dropped out
Incomplete outcome data (attrition bias):
All outcomes - ITT analysis
All outcomes
High risk Withdrawn participants were not analysed
Selective reporting (reporting bias) Unclear risk No study protocol
Similarity of baseline characteristics Low risk Baseline characteristics similar
Co-interventions avoided or similar Low risk Rescue analgesia: 500 mg paracetamol with a
maximum dose of 4000 mg/day
Compliance acceptable High risk 12 participants withdrew during treatment pe-
riod
Timing outcome assessments similar Low risk Timing similar
Hickey 1982
Methods RCT, double-blind
Participants 30 participants, 26 women, 4 men
Inclusion: incapacity due to low back pain, duration ≥ 6 months, age 21 to 75 years
Exclusion: pain from intervertebral disc prolapse, suspected neoplastic disease, neurolog-
ical disease, pregnancy, peptic ulceration or gastrointestinal haemorrhage, current treat-
ment with systemic corticosteroids or anticoagulants, liver or kidney disease, haemopoi-
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Hickey 1982 (Continued)
etic disorders, history of sensitivity to salicylates or paracetamol, psychiatric problems
Interventions NSAID (i): Diflunisal 1000 mg/day, 4 weeks (N = 16)
Reference treatment (ii): paracetamol 4000 mg/day, 4 weeks (N = 14)
Outcomes Number of participants with none or mild low back pain after 2 and 4 weeks: (i) 11, 13
(ii) 9, 7. Significantly more participants in (i) (10 out of 16) considered the therapy as
good or excellent than in (ii) (4 out of 12)
Adverse events: (i) 2 participants (ii) 1 participants
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomization prior to the trial
Allocation concealment (selection bias) Low risk Code-labelled drugs, code was not broken
Blinding (performance bias and detection
bias): All outcomes - Patients
All outcomes
Low risk Patients were blinded
Blinding (performance bias and detection
bias): All outcomes - Care providers
All outcomes
Low risk Care providers were blinded
Blinding (performance bias and detection
bias): All outcomes - Outcome assessors
All outcomes
Low risk Outcome assessors were blinded
Incomplete outcome data (attrition bias):
All outcomes - Drop-outs
All outcomes
Low risk Sixteen out of 16 participants and 13 out of 14 participants
completed the trial
Incomplete outcome data (attrition bias):
All outcomes - ITT analysis
All outcomes
High risk Two participants in the paracetamol group were not analysed in
their allocation group
Selective reporting (reporting bias) Unclear risk No protocol
Similarity of baseline characteristics Unclear risk No baseline characteristics were shown
Co-interventions avoided or similar Low risk Only anti-hypertensive drug therapy was allowed, other drugs
were forbidden
Compliance acceptable Unclear risk Compliance was not mentioned
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Hickey 1982 (Continued)
Timing outcome assessments similar Low risk Timing similar
Katz 2011
Methods RCT, double-blind
Participants 217 participants, 118 women, 99 men
Inclusion: participants aged≥ 18 years, body mass index≤ 39 kg/m², nonradiculopathic
low back pain for at least 3 months, required regular analgesic medication, analgesic
medication > 4 days/week over the previous month, average pain intensity score ≥ 4
over previous 24 hours on 11-point numerical rating scale, minimum compliance of 4
entries in electronic daily pain diary over the 5 previous days
Exclusion: radiculopathy in previous 2 years, secondary causes of back pain, surgical inter-
vention for treatment of back pain, pregnancy, lactation, rheumatoid arthritis, seronega-
tive spondyloarthropathy, Paget disease of spine, pelvis or femur, fibromyalgia, tumours
or infections of spinal cord, cancer in previous 2 years other than cutaneous basal cell
or squamous cell carcinoma, allergic reaction to monoclonal antibody or IgG-fusion
protein, acetaminophen or NSAIDs, contraindications to NSAID therapy
Interventions NSAID (i): naproxen 1000 mg daily and placebo single intravenous infusion, 12 weeks
(N = 88)
Reference treatment (ii): tanezumab single intravenous infusion 200 µg/kg and oral
placebo daily, 12 weeks (N = 88)
Reference treatment (iii): placebo single intravenous infusion and oral placebo daily, 12
weeks (N = 41)
Outcomes Mean change in average low back pain intensity over previous 24 hours on 11-point
numerical rating scale, at 6 weeks compared to baseline: (i versus iii) -2.5 versus -2.0 (P
= 0.068)
Adverse events: (i) 54 participants (3 withdrew); (ii) 50 participants (4 withdrew); (iii)
27 participants (2 withdrew)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not mentioned
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding (performance bias and detection
bias): All outcomes - Patients
All outcomes
Low risk Patients were blinded, placebo tablets/injections
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Katz 2011 (Continued)
Blinding (performance bias and detection
bias): All outcomes - Care providers
All outcomes
Unclear risk Unclear if care providers were blinded
Blinding (performance bias and detection
bias): All outcomes - Outcome assessors
All outcomes
Low risk Outcome assessors were blinded
Incomplete outcome data (attrition bias):
All outcomes - Drop-outs
All outcomes
High risk Drop out 32%
Incomplete outcome data (attrition bias):
All outcomes - ITT analysis
All outcomes
Low risk ITT was performed
Selective reporting (reporting bias) Low risk Trial was registered
Similarity of baseline characteristics Low risk Baseline characteristics were similar
Co-interventions avoided or similar Low risk Rescue medication acetaminophen with a maximum of 2000
mg per day and maximum 3 days per week
Compliance acceptable Low risk Nine people discontinued the trial
Timing outcome assessments similar Low risk Timing similar
Kivitz 2013
Methods Randomized, double-blind, placebo and active-controlled trial
Participants 1359 participants, 714 women, 645 men
Inclusion: duration of back pain of ≥ 3 months requiring regular use of analgesic med-
ication (> 4 days per week for the past month), including immediate-release opioids (in
which the average daily opioid dose (for a 7-day period) did not exceed a morphine
equivalent dose of 30 mg/d) but excluding acetaminophen, gabapentin or pregabalin as
the sole analgesics used for chronic low back pain; primary location of low back pain
between the 12th thoracic vertebra and the lower gluteal folds, with or without radiation
into the
posterior thigh (Quebec Task Force on Spinal Disorders category 1 or 2); average low
back pain intensity (LBPI) score of ≥ 4 (on an 11-point NRS) while receiving current
treatment; and Patient’s Global Assessment (PGA) of low back pain of fair, poor or very
poor
Exclusion: history of lumbosacral radiculopathywithin the past 2 years, vertebral fracture,
major trauma or back surgery in the past 6 months; significant cardiac, neurological, or
other pain, or psychological conditions; known history of rheumatoid arthritis, seroneg-
ative spondyloarthropathy, Paget’s disease of the spine, pelvis or femur, fibromyalgia,
tumours or infections of the spinal cord; and any condition that might preclude NSAID
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Kivitz 2013 (Continued)
use. Patients also were excluded if extended-release (ER) opioids or long-acting opioids
such as oxycodone controlled release, oxymorphone ER, hydromorphone, transdermal
fentanyl or methadone had been used within 3 months of screening
Interventions NSAID (i): naproxen 1000 mg daily and placebo infusion at baseline, 8 weeks and 16
weeks (N = 295)
Reference treatment (ii): placebo tablets daily and placebo infusion at baseline and 8
weeks, 16 weeks (N = 230)
Reference treatment (iii): tanezumab 5 mg iv infusion over 5 minutes at baseline and 8
weeks, 16 weeks (N = 232)
Reference treatment (iv): tanezumab 10 mg iv infusion over 5 minutes at baseline and 8
weeks, 16 weeks (N = 295)
Reference treatment (v): tanezumab 20 mg iv infusion over 5 minutes at baseline and 8
weeks, 16 weeks (N= 295)
Outcomes Least squares mean difference from baseline on a 11-point scale: (i versus iii) 0.08 (P =
0.688)
Least squares mean difference from baseline on a 11-point scale: (i versus iv) −0.39 (P
= 0.035)
Least squares mean difference from baseline on a 11-point scale: (i versus v) −0.51 (P =
0.006)
Adverse events: (i) 142 participants (10 withdrew), (ii) 120 participants (14 withdrew)
, (iii) 141 participants (11 withdrew), (iv) 171 participants (19 withdrew), (v) 190
participants (28 withdrew)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not mentioned
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding (performance bias and detection
bias): All outcomes - Patients
All outcomes
Low risk Patients were blinded
Blinding (performance bias and detection
bias): All outcomes - Care providers
All outcomes
Low risk Care providers were blinded
Blinding (performance bias and detection
bias): All outcomes - Outcome assessors
All outcomes
Unclear risk Not mentioned for all examinations
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Kivitz 2013 (Continued)
Incomplete outcome data (attrition bias):
All outcomes - Drop-outs
All outcomes
High risk All trial groups had high drop out rates
Incomplete outcome data (attrition bias):
All outcomes - ITT analysis
All outcomes
Unclear risk ITT and per protocol analysis used, unclear
which analysis was used in what compari-
son
Selective reporting (reporting bias) Low risk Protocol present
Similarity of baseline characteristics Low risk Baseline characteristics were comparable
Co-interventions avoided or similar Low risk Only paracetamol up to 300 mg/day and
max 3 days per week was allowed
Compliance acceptable Unclear risk Not mentioned
Timing outcome assessments similar Low risk Timing was similar
O’Donnell 2009
Methods RCT, double-blind, double-dummy
Participants 2 studies; study 1: 791 participants, 462 women, 329 men; study 2: 802 participants,
450 women, 342 men
Inclusion: participants aged ≥ 18 years, duration of back pain ≥ 12 weeks, requiring
analgesics ≥ 4 days/week, back pain score of ≥ 4 on 11-point NRS at baseline
Exclusion: back pain with neurologic aetiology, recent major trauma, due to visceral dis-
order, history of rheumatoid arthritis, spondyloarthropathy, spinal stenosis, malignancy,
fibromyalgia, tumours or infections of the brain, spinal cord or peripheral nerves, her-
niated disc with neurological impairment in previous 2 years, psoriasis, seizure disorder,
alcohol/analgesic/narcotic or other substance abuse in previous 2 years, asthma, allergic
reactions on aspirin or NSAID, contraindications for NSAID use, surgical intervention
for back pain in previous 6 months
Interventions NSAID (i): celecoxib 400 mg/day, 6 weeks (study 1: N = 402; study 2: N = 396)
Reference treatment (ii): tramadol 200 mg/day, 6 weeks (study 1: N = 389; study 2: N
= 396)
Outcomes At 6 weeks≥ 30% improvement in pain from baseline, measured with 11-point numer-
ical rating scale; study 1 (i versus ii) 63.2% versus 49.9% (P < 0.001); study 2 (i versus
ii) 64.1% versus 55.1% (P = 0.008)
Adverse events: study 1: (i) 191 participants (18 withdrew), (ii) 230 participants (72
withdrew); study 2: (i) 190 participants (21 withdrew), (ii) 224 participants (60 with-
drew)
Notes
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O’Donnell 2009 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomization was computer generated
Allocation concealment (selection bias) Low risk Computerized schedule
Blinding (performance bias and detection
bias): All outcomes - Patients
All outcomes
Low risk Double dummy, double blind
Blinding (performance bias and detection
bias): All outcomes - Care providers
All outcomes
Low risk Double dummy, double blind
Blinding (performance bias and detection
bias): All outcomes - Outcome assessors
All outcomes
Low risk Double dummy, double blind
Incomplete outcome data (attrition bias):
All outcomes - Drop-outs
All outcomes
High risk The tramadol group had a drop out rate > 20%
Incomplete outcome data (attrition bias):
All outcomes - ITT analysis
All outcomes
Low risk ITT analysis
Selective reporting (reporting bias) Unclear risk No study protocol
Similarity of baseline characteristics Low risk Baseline characteristics were similar
Co-interventions avoided or similar Low risk No rescue medication allowed
Compliance acceptable High risk Non-compliance in 9.6% of celecoxib group and
15% in tramadol group
Timing outcome assessments similar Low risk Timing similar
Romanò 2009
Methods RCT, cross-over design
Participants 42 participants, 20 women, 16 men
Inclusion: low back pain≥ 6 months due to disc prolapse, lumbar spondylosis or spinal
stenosis or both, minimum VAS > 40 mm, age 18 to 75
Exclusion: Previous back surgery, diabetes, neurological disease, cardio-renal disease,
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Romanò 2009 (Continued)
history of gastric ulcers or intestinal bleeding, known allergy to drugs under study,
alcohol/drugs abuse
Interventions Each treatment lasted 4 weeks with 1 week discontinuation between treatments
NSAID: (i) celecoxib approximately 3 to 6 mg/kg/day and placebo
Reference treatment: (ii) pregabalin approximately 1 mg/kg/day and placebo
Reference treatment: (iii) celecoxib and pregabalin
Outcomes Mean (SD) pain reduction after 4 weeks on 100 mm VAS: (i) 5.6; (ii) 5; (iii) 17.7;
Adverse events: (i) 4 participants (1 withdrew), (ii) 5 participants (1 withdrew), (iii) 7
participants (2 withdrew)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomization unclear
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding (performance bias and detection
bias): All outcomes - Patients
All outcomes
Unclear risk Not mentioned
Blinding (performance bias and detection
bias): All outcomes - Care providers
All outcomes
Unclear risk Not mentioned
Blinding (performance bias and detection
bias): All outcomes - Outcome assessors
All outcomes
Unclear risk Not mentioned
Incomplete outcome data (attrition bias):
All outcomes - Drop-outs
All outcomes
Low risk Low dropout rate
Incomplete outcome data (attrition bias):
All outcomes - ITT analysis
All outcomes
High risk Drop outs were excluded from data analysis
Selective reporting (reporting bias) Unclear risk No study protocol
Similarity of baseline characteristics Low risk Cross over design
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Romanò 2009 (Continued)
Co-interventions avoided or similar Low risk Use of antidepressants or anticonvulsants or both, opioids,
nonsteroidal anti-inflammatory drugs or muscle relaxants was
not permitted
Compliance acceptable Low risk Individual drug consumption was measured and acceptable
Timing outcome assessments similar Low risk Timing similar
Shirado 2010
Methods RCT
Participants 201 participants, 112 women, 89 men; mean age 42.2 years
Inclusion: age 20 to 64 years, nonspecific chronic low back pain ≥ 3 months without
radicular pain, ≥ 70° at straight leg raising test, negative femoral nerve stretching test,
no superficial sensory deficits, muscle strength ≥ 4/5
Exclusion: low back pain due to tumours, infections, fractures, previous back surgery,
severe osteoporosis, psychiatric disorders, liver and renal dysfunction, pregnancy, med-
ication for cardiac failure, history of cerebrovascular accident or myocardial infarction,
or both, in previous 6 months
Interventions NSAID (i): 1 of the following 3 NSAIDs were prescribed: loxoprofen sodium 180 mg/
day; diclofenac sodium 75 mg/day; zaltoprofen 240 mg/day, 12 weeks
Reference treatment (ii): exercise programme with trunk muscle strengthening and
stretching, 12 weeks
Outcomes Mean change from baseline to 8 weeks on 100 mm VAS was not different between (i)
and (ii), P = 0.33
Mean change from baseline to 8 weeks on RDQ in favour of (ii), P = 0.02
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated 4 block randomization
Allocation concealment (selection bias) Low risk Office manager concealed allocation
Blinding (performance bias and detection
bias): All outcomes - Patients
All outcomes
High risk NSAIDs versus exercise
Blinding (performance bias and detection
bias): All outcomes - Care providers
All outcomes
High risk NSAIDs versus exercise
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Shirado 2010 (Continued)
Blinding (performance bias and detection
bias): All outcomes - Outcome assessors
All outcomes
Low risk Outcome assessor was blinded
Incomplete outcome data (attrition bias):
All outcomes - Drop-outs
All outcomes
Low risk Two in exercise, 6 in NSAIDs.
Incomplete outcome data (attrition bias):
All outcomes - ITT analysis
All outcomes
High risk No ITT analysis performed.
Selective reporting (reporting bias) Unclear risk study protocol not attainable
Similarity of baseline characteristics Low risk Baseline characteristics were similar
Co-interventions avoided or similar Unclear risk Rescue medication not mentioned
Compliance acceptable Unclear risk Compliance not mentioned
Timing outcome assessments similar Low risk Timing similar
Videman 1984
Methods RCT, double-blind
Participants 28 outpatients, 11 women, 17 men; mean age 45 years
Inclusion: chronic severe low back pain, age 25 to 76 years
Exclusion: pregnant or nursing women, compensation claims, haematological, renal
or hepatic disease, pre-existing radiological evidence of peptic ulcer, intolerance to in-
domethacin
Interventions NSAID (i): piroxicam 20 mg/day, 6 weeks (N = 14)
NSAID (ii): indometacin 75 mg/day, 6 weeks (N = 14)
Outcomes Change of pain from baseline until 6 weeks: (i) 8.1 (ii) 9.4; no significant difference
between groups
Adverse events: (i) 8 participants (ii) 10 participants
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not mentioned
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Videman 1984 (Continued)
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding (performance bias and detection
bias): All outcomes - Patients
All outcomes
Low risk Patients were blinded
Blinding (performance bias and detection
bias): All outcomes - Care providers
All outcomes
Low risk Care providers were blinded
Blinding (performance bias and detection
bias): All outcomes - Outcome assessors
All outcomes
Low risk Outcome assessors were blinded
Incomplete outcome data (attrition bias):
All outcomes - Drop-outs
All outcomes
Low risk Two out of 14 participants in one group were lost to follow-up
Incomplete outcome data (attrition bias):
All outcomes - ITT analysis
All outcomes
High risk Complete case analysis
Selective reporting (reporting bias) Unclear risk No study protocol
Similarity of baseline characteristics Unclear risk No baseline characteristics shown
Co-interventions avoided or similar Low risk Only paracetamol as co-intervention up to 3000 mg
Compliance acceptable Unclear risk Compliance not mentioned
Timing outcome assessments similar Unclear risk Timing was unclear
Zerbini 2005
Methods RCT, double-blind, double-dummy, ’flare design’
Participants 446 participants, 320 women, 126 men; mean age (SD) 51.9 (13.8)
Inclusion: age 19 to 85 years, with chronic low back pain, regular users of analgesic
medication, pain without radiation to an extremity and without neurological signs or
pain with radiation to an extremity, but not below the knee and without neurological
signs, after 1 week washout period LBP intensity ≤ 80 mm on 100 mm VAS scale
Interventions NSAID (i) etoricoxib 60 mg/day, 4 weeks (N = 224)
NSAID (ii) diclofenac 150 mg/day, 4 weeks (N = 222)
Outcomes Mean difference (95% CI) pain intensity scale (100 mm VAS) at 4 weeks: (i, N = 222
versus ii, N = 218) 2.51 (−1.50 to 6.51)
Mean difference (95% CI) RDQ (0 to 24) over 4 weeks: (i versus ii) −0.23 (−1.14 to
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Zerbini 2005 (Continued)
0.67)
Adverse events: (i) 79 participants (15 withdrew); (ii) 87 participants (12 withdrew)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomization procedure not described
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding (performance bias and detection
bias): All outcomes - Patients
All outcomes
Low risk Double dummy
Blinding (performance bias and detection
bias): All outcomes - Care providers
All outcomes
Low risk Care providers blinded
Blinding (performance bias and detection
bias): All outcomes - Outcome assessors
All outcomes
Low risk Outcome assessors blinded
Incomplete outcome data (attrition bias):
All outcomes - Drop-outs
All outcomes
Low risk 9% and 11% drop out in both groups
Incomplete outcome data (attrition bias):
All outcomes - ITT analysis
All outcomes
High risk Per protocol analysis
Selective reporting (reporting bias) Unclear risk No study protocol
Similarity of baseline characteristics Low risk Similar baseline characteristics
Co-interventions avoided or similar Low risk Paracetamol as rescue therapy
Compliance acceptable Low risk More than 95% compliance in both study
groups
Timing outcome assessments similar Low risk Timing similar
Abbreviations: ESR: erythorcyte sedimentation rate, LBP: low back pain, NSAID: non-steroidal anti-inflammatory drug, RCT:
randomized controlled trial, RDQ: Roland Morris Disability Questionnaire, SD: standard deviation, VAS: visual analogue scale.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aoki 1983 Duration of back pain is unclear.
Babey-Dölle 1994 Only acute back pain included.
Borghi 2013 No comparison made, one study group.
Chang 2013 Patients were given intravenous infusion after spine surgery
Chrubasik 2003 Rofecoxib as study medication.
Davoli 1989 The trial only included participants with acute back pain.
Famaey 1998 The trial does not distinguish between participants with subacute and chronic back pain
Ingpen 1969 Duration of back pain is unclear.
Jacobs 1968 The study only included participants with acute back pain.
Jaffé 1974 Duration of back pain is unclear.
Katz 2003 Rofecoxib as study medication.
Listrat 1990 Duration of back pain is unclear.
Matsumo 1991 Inclusion > 1 month of back pain.
Merkulova 2013 Article in Russian.
Peng 2014 Article in Chinese.
Postacchini 1988 Inclusion > 2 months of back pain.
Siegmeth 1978 Participants selected based on radiological osteoarthritis, not on back pain
Tavafian 2014 NSAIDs were used in both groups as needed.
Waikakul 1995 Duration of back pain is unclear.
Waikakul 1996 Duration of back pain is unclear.
Wetzel 2014 Intravenous infusion in patients on chronic opioid treatment
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D A T A A N D A N A L Y S E S
Comparison 1. NSAIDs versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in pain intensity from
baseline on 100 mm VAS.
Follow-up ≤ 16 weeks.
6 Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 All NSAIDs 6 1354 Mean Difference (IV, Random, 95% CI) -6.97 [-10.74, -3.19]
1.2 Non-selective NSAIDs 4 847 Mean Difference (IV, Random, 95% CI) -5.96 [-10.96, -0.96]
1.3 Selective NSAIDs 2 507 Mean Difference (IV, Random, 95% CI) -9.11 [-13.56, -4.66]
2 Change in disability from
baseline
4 1161 Mean Difference (IV, Fixed, 95% CI) -0.85 [-1.30, -0.40]
3 Proportion of patients
experiencing adverse events.
Follow-up ≤ 16 weeks.
6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 All NSAIDs 6 1354 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.92, 1.17]
3.2 Non-selective NSAIDs 4 847 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.82, 1.08]
3.3 Selective NSAIDs 2 507 Risk Ratio (M-H, Fixed, 95% CI) 1.25 [1.00, 1.56]
4 Sensitivity analysis: change in
pain intensity from baseline on
100 mm VAS. Follow-up ≤ 16
weeks.
3 728 Mean Difference (IV, Random, 95% CI) -5.03 [-10.37, 0.32]
5 Sensitivity analysis: change in
disability from baseline
2 654 Mean Difference (IV, Fixed, 95% CI) -0.41 [-1.04, 0.23]
6 Sensitivity analysis: proportion
of patients experiencing adverse
events. Follow-up ≤ 16 weeks.
3 728 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.81, 1.07]
Comparison 2. NSAIDs versus other drug treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion of patients
experiencing global
improvement. Follow-up ≤ 6
weeks.
2 Risk Ratio (M-H, Random, 95% CI) Totals not selected
2 Proportion of patients
experiencing adverse events.
Follow-up ≤ 6 weeks.
3 Risk Ratio (M-H, Random, 95% CI) Totals not selected
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Analysis 1.1. Comparison 1 NSAIDs versus placebo, Outcome 1 Change in pain intensity from baseline on
100 mm VAS. Follow-up ≤ 16 weeks..
Review: Non-steroidal anti-inflammatory drugs for chronic low back pain
Comparison: 1 NSAIDs versus placebo
Outcome: 1 Change in pain intensity from baseline on 100 mm VAS. Follow-up≤ 16 weeks.
Study or subgroup NSAID Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 All NSAIDs
Allegrini 2009 60 -28 (31.7) 59 -16.5 (31.7) 8.4 % -11.50 [ -22.89, -0.11 ]
Berry 1982 37 -11.5 (34) 37 9.4 (34) 5.1 % -20.90 [ -36.39, -5.41 ]
Birbara 2003 107 -7.5 (23.3) 109 0 (23.3) 18.2 % -7.50 [ -13.71, -1.29 ]
Coats 2004 148 -41.9 (27.7) 143 -31.1 (27.7) 17.7 % -10.80 [ -17.17, -4.43 ]
Katz 2011 88 -2.4 (11.6) 41 0 (11.6) 24.5 % -2.40 [ -6.70, 1.90 ]
Kivitz 2013 295 -4.1 (22.3) 230 0 (22.3) 26.1 % -4.10 [ -7.94, -0.26 ]
Subtotal (95% CI) 735 619 100.0 % -6.97 [ -10.74, -3.19 ]
Heterogeneity: Tau2 = 10.35; Chi2 = 10.41, df = 5 (P = 0.06); I2 =52%
Test for overall effect: Z = 3.62 (P = 0.00030)
2 Non-selective NSAIDs
Allegrini 2009 60 -28 (31.7) 59 -16.5 (31.7) 14.1 % -11.50 [ -22.89, -0.11 ]
Berry 1982 37 -11.5 (34) 37 9.4 (34) 8.7 % -20.90 [ -36.39, -5.41 ]
Katz 2011 88 -2.4 (11.6) 41 0 (11.6) 37.5 % -2.40 [ -6.70, 1.90 ]
Kivitz 2013 295 -4.1 (22.3) 230 0 (22.3) 39.7 % -4.10 [ -7.94, -0.26 ]
Subtotal (95% CI) 480 367 100.0 % -5.96 [ -10.96, -0.96 ]
Heterogeneity: Tau2 = 12.54; Chi2 = 6.70, df = 3 (P = 0.08); I2 =55%
Test for overall effect: Z = 2.34 (P = 0.019)
3 Selective NSAIDs
Birbara 2003 107 -7.5 (23.3) 109 0 (23.3) 51.2 % -7.50 [ -13.71, -1.29 ]
Coats 2004 148 -41.9 (27.7) 143 -31.1 (27.7) 48.8 % -10.80 [ -17.17, -4.43 ]
Subtotal (95% CI) 255 252 100.0 % -9.11 [ -13.56, -4.66 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.53, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 4.02 (P = 0.000059)
Test for subgroup differences: Chi2 = 0.94, df = 2 (P = 0.63), I2 =0.0%
-20 -10 0 10 20
Favours NSAID Favours placebo
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Analysis 1.2. Comparison 1 NSAIDs versus placebo, Outcome 2 Change in disability from baseline.
Review: Non-steroidal anti-inflammatory drugs for chronic low back pain
Comparison: 1 NSAIDs versus placebo
Outcome: 2 Change in disability from baseline
Study or subgroup NSAID Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Birbara 2003 107 -2.1 (5.3) 109 0 (5.3) 10.1 % -2.10 [ -3.51, -0.69 ]
Coats 2004 148 -1.1 (3.1) 143 0 (3.1) 39.7 % -1.10 [ -1.81, -0.39 ]
Katz 2011 88 -0.6 (3.1) 41 0 (3.1) 15.3 % -0.60 [ -1.75, 0.55 ]
Kivitz 2013 295 -0.32 (4.4) 230 0 (4.4) 35.0 % -0.32 [ -1.08, 0.44 ]
Total (95% CI) 638 523 100.0 % -0.85 [ -1.30, -0.40 ]
Heterogeneity: Chi2 = 5.53, df = 3 (P = 0.14); I2 =46%
Test for overall effect: Z = 3.72 (P = 0.00020)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours experimental Favours control
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Analysis 1.3. Comparison 1 NSAIDs versus placebo, Outcome 3 Proportion of patients experiencing
adverse events. Follow-up ≤ 16 weeks..
Review: Non-steroidal anti-inflammatory drugs for chronic low back pain
Comparison: 1 NSAIDs versus placebo
Outcome: 3 Proportion of patients experiencing adverse events. Follow-up≤ 16 weeks.
Study or subgroup NSAID Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 All NSAIDs
Allegrini 2009 5/60 3/59 1.1 % 1.64 [ 0.41, 6.55 ]
Berry 1982 18/37 18/37 6.5 % 1.00 [ 0.63, 1.60 ]
Birbara 2003 56/107 51/109 18.1 % 1.12 [ 0.85, 1.46 ]
Coats 2004 52/148 35/143 12.8 % 1.44 [ 1.00, 2.06 ]
Katz 2011 54/88 27/41 13.2 % 0.93 [ 0.71, 1.23 ]
Kivitz 2013 142/295 120/230 48.4 % 0.92 [ 0.78, 1.09 ]
Subtotal (95% CI) 735 619 100.0 % 1.04 [ 0.92, 1.17 ]
Total events: 327 (NSAID), 254 (Placebo)
Heterogeneity: Chi2 = 6.22, df = 5 (P = 0.28); I2 =20%
Test for overall effect: Z = 0.61 (P = 0.54)
2 Non-selective NSAIDs
Allegrini 2009 5/60 3/59 1.6 % 1.64 [ 0.41, 6.55 ]
Berry 1982 18/37 18/37 9.3 % 1.00 [ 0.63, 1.60 ]
Katz 2011 54/88 27/41 19.1 % 0.93 [ 0.71, 1.23 ]
Kivitz 2013 142/295 120/230 70.0 % 0.92 [ 0.78, 1.09 ]
Subtotal (95% CI) 480 367 100.0 % 0.94 [ 0.82, 1.08 ]
Total events: 219 (NSAID), 168 (Placebo)
Heterogeneity: Chi2 = 0.74, df = 3 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 0.82 (P = 0.41)
3 Selective NSAIDs
Birbara 2003 56/107 51/109 58.7 % 1.12 [ 0.85, 1.46 ]
Coats 2004 52/148 35/143 41.3 % 1.44 [ 1.00, 2.06 ]
Subtotal (95% CI) 255 252 100.0 % 1.25 [ 1.00, 1.56 ]
Total events: 108 (NSAID), 86 (Placebo)
Heterogeneity: Chi2 = 1.21, df = 1 (P = 0.27); I2 =18%
Test for overall effect: Z = 1.99 (P = 0.046)
Test for subgroup differences: Chi2 = 4.53, df = 2 (P = 0.10), I2 =56%
0.2 0.5 1 2 5
Favours NSAID Favours placebo
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Analysis 1.4. Comparison 1 NSAIDs versus placebo, Outcome 4 Sensitivity analysis: change in pain intensity
from baseline on 100 mm VAS. Follow-up ≤ 16 weeks..
Review: Non-steroidal anti-inflammatory drugs for chronic low back pain
Comparison: 1 NSAIDs versus placebo
Outcome: 4 Sensitivity analysis: change in pain intensity from baseline on 100 mm VAS. Follow-up≤ 16 weeks.
Study or subgroup NSAID Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Berry 1982 37 -11.5 (34) 37 9.4 (34) 10.0 % -20.90 [ -36.39, -5.41 ]
Katz 2011 88 -2.4 (11.6) 41 0 (11.6) 43.7 % -2.40 [ -6.70, 1.90 ]
Kivitz 2013 295 -4.1 (22.3) 230 0 (22.3) 46.3 % -4.10 [ -7.94, -0.26 ]
Total (95% CI) 420 308 100.0 % -5.03 [ -10.37, 0.32 ]
Heterogeneity: Tau2 = 12.20; Chi2 = 5.10, df = 2 (P = 0.08); I2 =61%
Test for overall effect: Z = 1.84 (P = 0.065)
Test for subgroup differences: Not applicable
-50 -25 0 25 50
Favours NSAID Favours placebo
Analysis 1.5. Comparison 1 NSAIDs versus placebo, Outcome 5 Sensitivity analysis: change in disability
from baseline.
Review: Non-steroidal anti-inflammatory drugs for chronic low back pain
Comparison: 1 NSAIDs versus placebo
Outcome: 5 Sensitivity analysis: change in disability from baseline
Study or subgroup NSAID Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Katz 2011 88 -0.6 (3.1) 41 0 (3.1) 30.4 % -0.60 [ -1.75, 0.55 ]
Kivitz 2013 295 -0.32 (4.4) 230 0 (4.4) 69.6 % -0.32 [ -1.08, 0.44 ]
Total (95% CI) 383 271 100.0 % -0.41 [ -1.04, 0.23 ]
Heterogeneity: Chi2 = 0.16, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 1.25 (P = 0.21)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours experimental Favours control
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Analysis 1.6. Comparison 1 NSAIDs versus placebo, Outcome 6 Sensitivity analysis: proportion of patients
experiencing adverse events. Follow-up ≤ 16 weeks..
Review: Non-steroidal anti-inflammatory drugs for chronic low back pain
Comparison: 1 NSAIDs versus placebo
Outcome: 6 Sensitivity analysis: proportion of patients experiencing adverse events. Follow-up≤ 16 weeks.
Study or subgroup NSAID Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Berry 1982 18/37 18/37 9.5 % 1.00 [ 0.63, 1.60 ]
Katz 2011 54/88 27/41 19.4 % 0.93 [ 0.71, 1.23 ]
Kivitz 2013 142/295 120/230 71.1 % 0.92 [ 0.78, 1.09 ]
Total (95% CI) 420 308 100.0 % 0.93 [ 0.81, 1.07 ]
Total events: 214 (NSAID), 165 (Placebo)
Heterogeneity: Chi2 = 0.10, df = 2 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.99 (P = 0.32)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours NSAID Favours placebo
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Analysis 2.1. Comparison 2 NSAIDs versus other drug treatment, Outcome 1 Proportion of patients
experiencing global improvement. Follow-up ≤ 6 weeks..
Review: Non-steroidal anti-inflammatory drugs for chronic low back pain
Comparison: 2 NSAIDs versus other drug treatment
Outcome: 1 Proportion of patients experiencing global improvement. Follow-up≤ 6 weeks.
Study or subgroup NSAID Other drug Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Hickey 1982 13/16 7/12 1.39 [ 0.82, 2.37 ]
O’Donnell 2009 504/798 392/785 1.26 [ 1.16, 1.38 ]
0.2 0.5 1 2 5
favours other drug favours NSAID
Analysis 2.2. Comparison 2 NSAIDs versus other drug treatment, Outcome 2 Proportion of patients
experiencing adverse events. Follow-up ≤ 6 weeks..
Review: Non-steroidal anti-inflammatory drugs for chronic low back pain
Comparison: 2 NSAIDs versus other drug treatment
Outcome: 2 Proportion of patients experiencing adverse events. Follow-up≤ 6 weeks.
Study or subgroup NSAID Other drug Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Hickey 1982 2/16 1/12 1.50 [ 0.15, 14.68 ]
O’Donnell 2009 381/798 454/785 0.83 [ 0.75, 0.91 ]
Roman 2009 4/36 5/36 0.80 [ 0.23, 2.74 ]
0.05 0.2 1 5 20
Favours NSAID Favours other drug
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
Last searched 24 June 2015. Line 34 is added and line 42 is revised.
#1 MeSH descriptor: [Back Pain] explode all trees
#2 dorsalgia
#3 backache
#4 lumbar next pain or coccyx or coccydynia or spondylosis
#5 MeSH descriptor: [Spine] explode all trees
#6 MeSH descriptor: [Spinal Diseases] explode all trees
#7 lumbago and discitis and disc near herniation
#8 spinal fusion
#9 spinal neoplasms
#10 facet near joints
#11 MeSH descriptor: [Intervertebral Disk] explode all trees
#12 postlaminectomy
#13 arachnoiditis
#14 failed near back
#15 MeSH descriptor: [Cauda Equina] explode all trees
#16 lumbar near vertebra*
#17 spinal near stenosis
#18 slipped near (disc* or disk*)
#19 degenerat* near (disc* or disk*)
#20 stenosis near (spine or root or spinal)
#21 displace* near (disc* or disk*)
#22 prolap* near (disc* or disk*)
#23 MeSH descriptor: [Sciatic Neuropathy] explode all trees
#24 sciatic*
#25 back disorder*
#26 back near pain
#27 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #
20 or #21 or #22 or #23 or #24 or #25 or #26
#28 nsaid*
#29 MeSH descriptor: [Anti-Inflammatory Agents, Non-Steroidal] explode all trees
#30 MeSH descriptor: [Cyclooxygenase Inhibitors] explode all trees
#31 MeSH descriptor: [Cyclooxygenase 2 Inhibitors] explode all trees
#32 non-steroidal anti inflammat*
#33 non-steroidal anti-inflammat*
#34 (cyclooxygenase or cyclo-oxygenase) next/3 inhibitor*
#35 aspirin
#36 acetylsalicyl*
#37 carbasalate calcium
#38 diflunisal
#39 aceclofenac
#40 alclofenac
#41 diclofenac
#42 indometacin or indomethacin
#43 sulindac
#44 meloxicam
#45 piroxicam
#46 dexibuprofen
#47 dexketoprofen
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#48 fenoprofen
#49 flurbiprofen
#50 ibuprofen
#51 ketoprofen
#52 naproxen
#53 tiapro*
#54 metamizol
#55 phenylbutazone
#56 phenazone
#57 propyphenazone
#58 celecoxib
#59 etoricoxib
#60 nabumeton
#61 parecoxib
#62 rofecoxib
#63 celecoxib
#64 valdecoxib
#65 lumiracoxib
#66 parecoxib
#67 vioxx
#68 celebrex
#69 bextra
#70 prexige
#71 arcoxia
#72 etodolac
#73 floctafenine
#74 meclofenam*
#75 meloxicam
#76 oxaprozin
#77 piroxicam
#78 tenoxicam
#79 tolmetin
#80 #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or #45
or #46 or #47 or #48 or #49 or #50 or #51 or #52 or #53 or #54 or #55 or #56 or #57 or #58 or #59 or #60 or #61 or #62 or #63 or
#64 or #65 or #66 or #67 or #68 or #69 or #70 or #71 or #72 or #73 or #74 or #75 or #76 or #77 or #78 or #79
#81 #27 and #80
#82 #81 in Trials
May 2012 strategy. In 2015, Line 77 and 66 are removed (duplicate with line 52 and 59), disc degeneration and prolapse are removed
from line 8 (captured in line 20 and 23), and sciatica is removed from line 5 (captured in line 25).
#1 MeSH descriptor Back Pain explode all trees
#2 dorsalgia
#3 backache
#4 MeSH descriptor Low Back Pain explode all trees
#5 (lumbar next pain) or (coccyx) or (coccydynia) or (sciatica) or (spondylosis)
#6 MeSH descriptor Spine explode all trees
#7 MeSH descriptor Spinal Diseases explode all trees
#8 (lumbago) or (discitis) or (disc near degeneration) or (disc near prolapse) or (disc near herniation)
#9 spinal fusion
#10 spinal neoplasms
#11 facet near joints
#12 MeSH descriptor Intervertebral Disk explode all trees
#13 postlaminectomy
#14 arachnoiditis 36
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#15 failed near back
#16 MeSH descriptor Cauda Equina explode all trees
#17 lumbar near vertebra*
#18 spinal near stenosis
#19 slipped near (disc* or disk*)
#20 degenerat* near (disc* or disk*)
#21 stenosis near (spine or root or spinal)
#22 displace* near (disc* or disk*)
#23 prolap* near (disc* or disk*)
#24 MeSH descriptor Sciatic Neuropathy explode all trees
#25 sciatic*
#26 back disorder*
#27 back near pain
#28 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16
OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27)
#29 nsaid*
#30 MeSH descriptor Anti-Inflammatory Agents, Non-Steroidal explode all trees
#31 MeSH descriptor Cyclooxygenase Inhibitors explode all trees
#32 MeSH descriptor Cyclooxygenase 2 Inhibitors explode all trees
#33 non-steroidal anti inflammat*
#34 non-steroidal anti-inflammat*
#35 aspirin
#36 acetylsalicyl*
#37 carbasalate calcium
#38 diflunisal
#39 aceclofenac
#40 alclofenac
#41 diclofenac
#42 indometacin
#43 sulindac
#44 meloxicam
#45 piroxicam
#46 dexibuprofen
#47 dexketoprofen
#48 fenoprofen
#49 flurbiprofen
#50 ibuprofen
#51 ketoprofen
#52 naproxen
#53 tiapro*
#54 metamizol
#55 phenylbutazone
#56 phenazone
#57 propyphenazone
#58 celecoxib
#59 etoricoxib
#60 nabumeton
#61 parecoxib
#62 rofecoxib
#63 celecoxib
#64 valdecoxib
#65 lumiracoxib
#66 etoricoxib
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#67 parecoxib
#68 vioxx
#69 celebrex
#70 bextra
#71 prexige
#72 arcoxia
#73 etodolac
#74 floctafenine
#75 meclofenam*
#76 meloxicam
#77 naproxen
#78 oxaprozin
#79 piroxicam
#80 tenoxicam
#81 tolmetin
#82 (#29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43
OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #52 OR #53 OR #54 OR #55 OR #56 OR #57 OR #58
OR #59 OR #60 OR #61 OR #62 OR #63 OR #64 OR #65 OR #66 OR #67 OR #68 OR #69 OR #70 OR #71 OR #72 OR #73
OR #74 OR #75 OR #76 OR #77 OR #78 OR #79 OR #80 OR #81)
#83 (#28 AND #82), from 2007 to 2012
Appendix 2. MEDLINE search strategy
Last searched 24 June 2015. Line 3 and 61 are added and line 6, 22, 29, and 39 are revised.
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. pragmatic clinical trial.pt.
4. comparative study.pt.
5. clinical trial.pt.
6. randomi#ed.ab.
7. placebo.ab,ti.
8. drug therapy.fs.
9. randomly.ab,ti.
10. trial.ab,ti.
11. groups.ab,ti.
12. or/1-11
13. (animals not (humans and animals)).sh.
14. 12 not 13
15. dorsalgia.ti,ab.
16. exp Back Pain/
17. backache.ti,ab.
18. (lumbar adj pain).ti,ab.
19. coccyx.ti,ab.
20. coccydynia.ti,ab.
21. sciatica.ti,ab.
22. exp sciatic neuropathy/
23. spondylosis.ti,ab.
24. lumbago.ti,ab.
25. back disorder$.ti,ab.
26. or/15-25
27. exp Anti-Inflammatory Agents, Non-Steroidal/
28. nsaids.mp.
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29. non-steroidal antiinflammat$.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]
30. non-steroidal anti-inflammat$.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]
31. aspirin.mp. or exp Aspirin/
32. acetylsalicyl$.mp.
33. exp Salicylic Acid/
34. carbasalate calcium.mp.
35. diflunisal.mp. or exp Diflunisal/
36. aceclofenac.mp.
37. alclofenac.mp.
38. diclofenac.mp. or exp Diclofenac/
39. (indometacin or indomethacin).mp. or exp Indomethacin/
40. sulindac.mp. or exp Sulindac/
41. meloxicam.mp.
42. piroxicam.mp. or exp Piroxicam/
43. dexibuprofen.mp.
44. dexketoprofen.mp.
45. fenoprofen.mp. or exp Fenoprofen/
46. flurbiprofen.mp. or exp Flurbiprofen/
47. ibuprofen.mp. or exp Ibuprofen/
48. ketoprofen.mp. or exp Ketoprofen/
49. naproxen.mp. or exp Naproxen/
50. tiapro$.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol
supplementary concept word, rare disease supplementary concept word, unique identifier]
51. metamizol.mp. or exp Dipyrone/
52. phenylbutazone.mp. or exp Phenylbutazone/
53. phenazone.mp. or exp Antipyrine/
54. propyphenazone.mp.
55. celecoxib.mp.
56. etoricoxib.mp.
57. nabumeton.mp.
58. parecoxib.mp.
59. or/27-58
60. exp cyclooxygenase inhibitors/ or exp cyclooxygenase 2 inhibitors/
61. ((cyclooxygenase or cyclo-oxygenase) adj3 inhibitor*).mp.
62. rofecoxib.mp.
63. celecoxib.mp.
64. valdecoxib.mp.
65. lumiracoxib.mp.
66. etoricoxib.mp.
67. parecoxib.mp.
68. vioxx.mp.
69. celebrex.mp.
70. bextra.mp.
71. prexige.mp.
72. arcoxia.mp.
73. etodolac.mp. or exp Etodolac/
74. floctafenine.mp.
75. exp Meclofenamic Acid/
76. meclofenamate.mp.
77. meloxicam.mp.
78. oxaprozin.mp.
54Non-steroidal anti-inflammatory drugs for chronic low back pain (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
79. piroxicam.mp. or exp Piroxicam/
80. tenoxicam.mp.
81. tolmetin.mp. or exp Tolmetin/
82. or/60-81
83. 59 or 82
84. 14 and 26 and 83
85. limit 84 to yr=2014-2015
86. limit 84 to ed=20140410-20150624
87. 85 or 86
May 2012 strategy. Line 77 is removed in 2015 (duplicate with line 49).
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. comparative study.pt.
4. clinical trial.pt.
5. randomized.ab.
6. placebo.ab,ti.
7. drug therapy.fs.
8. randomly.ab,ti.
9. trial.ab,ti.
10. groups.ab,ti.
11. or/1-10
12. (animals not (humans and animals)).sh.
13. 11 not 12
14. dorsalgia.ti,ab.
15. exp Back Pain/
16. backache.ti,ab.
17. exp Low Back Pain/
18. (lumbar adj pain).ti,ab.
19. coccyx.ti,ab.
20. coccydynia.ti,ab.
21. sciatica.ti,ab.
22. sciatic neuropathy/
23. spondylosis.ti,ab.
24. lumbago.ti,ab.
25. back disorder$.ti,ab.
26. or/14-25 33294
27. exp Anti-Inflammatory Agents, Non-Steroidal/
28. nsaids.mp.
29. non-steroidal anti inflammat$.mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol
supplementary concept, rare disease supplementary concept, unique identifier]
30. non-steroidal anti-inflammat$.mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol
supplementary concept, rare disease supplementary concept, unique identifier]
31. aspirin.mp. or exp Aspirin/
32. acetylsalicyl$.mp.
33. exp Salicylic Acid/
34. carbasalate calcium.mp.
35. diflunisal.mp. or exp Diflunisal/
36. aceclofenac.mp.
37. alclofenac.mp.
38. diclofenac.mp. or exp Diclofenac/
39. indometacin.mp. or exp Indomethacin/
40. sulindac.mp. or exp Sulindac/
41. meloxicam.mp.
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42. piroxicam.mp. or exp Piroxicam/
43. dexibuprofen.mp.
44. dexketoprofen.mp.
45. fenoprofen.mp. or exp Fenoprofen/
46. flurbiprofen.mp. or exp Flurbiprofen/
47. ibuprofen.mp. or exp Ibuprofen/
48. ketoprofen.mp. or exp Ketoprofen/
49. naproxen.mp. or exp Naproxen/
50. tiapro$.mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept,
rare disease supplementary concept, unique identifier]
51. metamizol.mp. or exp Dipyrone/
52. phenylbutazone.mp. or exp Phenylbutazone/
53. phenazone.mp. or exp Antipyrine/
54. propyphenazone.mp.
55. celecoxib.mp.
56. etoricoxib.mp.
57. nabumeton.mp.
58. parecoxib.mp.
59. or/27-58
60. exp cyclooxygenase inhibitors/ or exp cyclooxygenase 2 inhibitors/
61. rofecoxib.mp.
62. celecoxib.mp.
63. valdecoxib.mp.
64. lumiracoxib.mp.
65. etoricoxib.mp.
66. parecoxib.mp.
67. vioxx.mp.
68. celebrex.mp.
69. bextra.mp.
70. prexige.mp.
71. arcoxia.mp.
72. etodolac.mp. or exp Etodolac/
73. floctafenine.mp.
74. exp Meclofenamic Acid/
75. meclofenamate.mp.
76. meloxicam.mp.
77. naproxen.mp. or exp Naproxen/
78. oxaprozin.mp.
79. piroxicam.mp. or exp Piroxicam/
80. tenoxicam.mp.
81. tolmetin.mp. or exp Tolmetin/
82. or/60-81
83. 59 or 82
84. 13 and 26 and 83
85. limit 84 to yr=“2007 - 2012”
86. limit 84 to ed=20070601-20120524
87. 85 or 86
56Non-steroidal anti-inflammatory drugs for chronic low back pain (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Appendix 3. MEDLINE In-Process & Other Non-Indexed Citations
Last searched 24 June 2015. Line 3 is added, line 6, 27, 37, and 58 are revised.
1. randomized controlled trial.ti,ab.
2. controlled clinical trial.ti,ab.
3. pragmatic.ti,ab.
4. comparative study.ti,ab.
5. clinical trial.ti,ab.
6. randomi#ed.ab.
7. placebo.ab,ti.
8. drug therapy.fs.
9. randomly.ab,ti.
10. trial.ab,ti.
11. groups.ab,ti.
12. or/1-11
13. dorsalgia.ti,ab.
14. Back Pain.ti,ab.
15. backache.ti,ab.
16. (lumbar adj pain).ti,ab.
17. coccyx.ti,ab.
18. coccydynia.ti,ab.
19. sciatica.ti,ab.
20. sciatic neuropathy.ti,ab.
21. spondylosis.ti,ab.
22. lumbago.ti,ab.
23. back disorder$.ti,ab.
24. or/13-23
25. Anti-Inflammatory Agents, Non-Steroidal.mp.
26. nsaids.mp.
27. non-steroidal antiinflammat$.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]
28. non-steroidal anti-inflammat$.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]
29. aspirin.mp.
30. acetylsalicyl$.mp.
31. Salicylic Acid.mp.
32. carbasalate calcium.mp.
33. diflunisal.mp.
34. aceclofenac.mp.
35. alclofenac.mp.
36. diclofenac.mp.
37. (indomethacin or indometacin).mp.
38. sulindac.mp.
39. meloxicam.mp.
40. piroxicam.mp.
41. dexibuprofen.mp.
42. dexketoprofen.mp.
43. fenoprofen.mp.
44. flurbiprofen.mp.
45. ibuprofen.mp.
46. ketoprofen.mp.
47. naproxen.mp.
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48. tiapro$.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol
supplementary concept word, rare disease supplementary concept word, unique identifier]
49. metamizol.mp.
50. phenylbutazone.mp.
51. phenazone.mp.
52. propyphenazone.mp.
53. celecoxib.mp.
54. etoricoxib.mp.
55. nabumeton.mp.
56. parecoxib.mp.
57. or/25-56
58. ((cyclooxygenase or cyclo-oxygenase) adj3 inhibitor*).mp.
59. rofecoxib.mp.
60. celecoxib.mp.
61. valdecoxib.mp.
62. lumiracoxib.mp.
63. etoricoxib.mp.
64. parecoxib.mp.
65. vioxx.mp.
66. celebrex.mp.
67. bextra.mp.
68. prexige.mp.
69. arcoxia.mp.
70. etodolac.mp.
71. floctafenine.mp.
72. Meclofenamic Acid.mp.
73. meclofenamate.mp.
74. meloxicam.mp.
75. oxaprozin.mp.
76. piroxicam.mp.
77. tenoxicam.mp.
78. tolmetin.mp.
79. or/58-78
80. 57 or 79
81. 12 and 24 and 80
82. limit 81 to yr=2014-2015
83. limit 81 to ed=20140410-20150624
84. 82 or 83
April 2014 search strategy
1. randomized controlled trial.ti,ab.
2. controlled clinical trial.ti,ab.
3. comparative study.ti,ab.
4. clinical trial.ti,ab.
5. randomized.ab.
6. placebo.ab,ti.
7. drug therapy.fs.
8. randomly.ab,ti.
9. trial.ab,ti.
10. groups.ab,ti.
11. or/1-10
12. dorsalgia.ti,ab.
13. Back Pain.ti,ab.
14. backache.ti,ab.
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15. (lumbar adj pain).ti,ab.
16. coccyx.ti,ab.
17. coccydynia.ti,ab.
18. sciatica.ti,ab.
19. sciatic neuropathy.ti,ab.
20. spondylosis.ti,ab.
21. lumbago.ti,ab.
22. back disorder$.ti,ab.
23. or/12-22
24. Anti-Inflammatory Agents, Non-Steroidal.mp.
25. nsaids.mp.
26. non-steroidal anti inflammat$.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]
27. non-steroidal anti-inflammat$.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]
28. aspirin.mp.
29. acetylsalicyl$.mp.
30. Salicylic Acid.mp.
31. carbasalate calcium.mp.
32. diflunisal.mp.
33. aceclofenac.mp.
34. alclofenac.mp.
35. diclofenac.mp.
36. indomethacin.mp.
37. sulindac.mp.
38. meloxicam.mp.
39. piroxicam.mp.
40. dexibuprofen.mp.
41. dexketoprofen.mp.
42. fenoprofen.mp.
43. flurbiprofen.mp.
44. ibuprofen.mp.
45. ketoprofen.mp.
46. naproxen.mp.
47. tiapro$.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol
supplementary concept word, rare disease supplementary concept word, unique identifier]
48. metamizol.mp.
49. phenylbutazone.mp.
50. phenazone.mp.
51. propyphenazone.mp.
52. celecoxib.mp.
53. etoricoxib.mp.
54. nabumeton.mp.
55. parecoxib.mp.
56. or/24-55
57. (cyclooxygenase inhibitors or cyclooxygenase 2 inhibitors).mp.
58. rofecoxib.mp.
59. celecoxib.mp.
60. valdecoxib.mp.
61. lumiracoxib.mp.
62. etoricoxib.mp.
63. parecoxib.mp.
64. vioxx.mp.
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65. celebrex.mp.
66. bextra.mp.
67. prexige.mp.
68. arcoxia.mp.
69. etodolac.mp.
70. floctafenine.mp.
71. Meclofenamic Acid.mp.
72. meclofenamate.mp.
73. meloxicam.mp.
74. oxaprozin.mp.
75. piroxicam.mp.
76. tenoxicam.mp.
77. tolmetin.mp.
78. or/57-77
79. 56 or 78
80. 11 and 23 and 79
Appendix 4. EMBASE search strategy
Last searched 24 June 2015. The study design filter, line 38, and line 46 are revised and line 68 is added.
1. Randomized Controlled Trial/ (374656)
2. exp Controlled Clinical Trial/ (511712)
3. Controlled Study/ (4627382)
4. Double Blind Procedure/ (121249)
5. Single Blind Procedure/ (20436)
6. crossover procedure/ (43275)
7. placebo/ (258120)
8. allocat$.mp. (105697)
9. assign$.mp. (262956)
10. blind$.mp. (343130)
11. ((control$ or compar$ or prospectiv$ or clinical) adj25 (trial or study)).mp. (7800092)
12. (crossover or cross-over).mp. (81850)
13. factorial$.mp. (50965)
14. (followup or follow-up).mp. (1253262)
15. placebo$.mp. (339829)
16. random$.mp. (1133643)
17. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).mp. (222737)
18. volunteer$.mp. (196350)
19. or/1-18 (8994276)
20. exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/
(21299526)
21. human/ or normal human/ or human cell/ (15984909)
22. 20 and 21 (15952556)
23. 20 not 22 (5346970)
24. 19 not 23 (6914940)
25. dorsalgia.mp. (102)
26. back pain.mp. (59723)
27. exp BACKACHE/ (73517)
28. (lumbar adj pain).mp. (1626)
29. coccyx.mp. (800)
30. coccydynia.mp. (120)
31. sciatica.mp. (4597)
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32. exp ISCHIALGIA/ (5449)
33. spondylosis.mp. (7198)
34. lumbago.mp. (1454)
35. or/25-34 (93822)
36. exp Nonsteroid Antiinflammatory Agent/ (444580)
37. nsaids.mp. (24138)
38. non-steroidal anti-inflammator$.mp. (16629)
39. exp Acetylsalicylic Acid/ (161086)
40. acetylsalicyl$.mp. (163662)
41. carbasalate calcium.mp. or exp Carbasalate Calcium/ (242)
42. diflunisal.mp. or exp DIFLUNISAL/ (2399)
43. aceclofenac.mp. or exp ACECLOFENAC/ (1287)
44. alclofenac.mp. or exp ALCLOFENAC/ (355)
45. diclofenac.mp. or exp DICLOFENAC/ (32204)
46. exp INDOMETACIN/ or (indometacin or indomethacin).mp. (70465)
47. sulindac.mp. or exp SULINDAC/ (6849)
48. meloxicam.mp. or exp MELOXICAM/ (4723)
49. exp PIROXICAM/ or piroxicam.mp. (10561)
50. dexibuprofen.mp. or exp DEXIBUPROFEN/ (212)
51. dexketoprofen.mp. or exp DEXKETOPROFEN/ (463)
52. exp FENOPROFEN/ or fenoprofen.mp. (2484)
53. flurbiprofen.mp. or exp FLURBIPROFEN/ (6927)
54. ibuprofen.mp. or exp IBUPROFEN/ (39286)
55. ketoprofen.mp. or exp KETOPROFEN/ (10969)
56. naproxen.mp. or exp NAPROXEN/ (22293)
57. tiapro$.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device
trade name, keyword] (1330)
58. metamizol.mp. or exp Dipyrone/ (6416)
59. phenylbutazone.mp. or exp PHENYLBUTAZONE/ (11876)
60. phenazone.mp. or exp PHENAZONE/ (5587)
61. exp PROPYPHENAZONE/ or propyphenazone.mp. (829)
62. celecoxib.mp. or exp CELECOXIB/ (17414)
63. etoricoxib.mp. or exp ETORICOXIB/ (2236)
64. exp Nabumetone/ or nabumeton.mp. (1837)
65. parecoxib.mp. or exp PARECOXIB/ (1501)
66. or/36-65 (464519)
67. exp Cyclooxygenase 2 Inhibitor/ (41240)
68. ((cyclooxygenase or cyclo-oxygenase) adj3 inhibitor*).mp. (27816)
69. rofecoxib.mp. or exp ROFECOXIB/ (9957)
70. valdecoxib.mp. or exp VALDECOXIB/ (2464)
71. lumiracoxib.mp. or exp LUMIRACOXIB/ (1046)
72. etoricoxib.mp. or exp ETORICOXIB/ (2236)
73. parecoxib.mp. or exp PARECOXIB/ (1501)
74. vioxx.mp. (2888)
75. celebrex.mp. (2353)
76. bextra.mp. (569)
77. prexige.mp. (174)
78. arcoxia.mp. (276)
79. etodolac.mp. or exp ETODOLAC/ (2403)
80. floctafenine.mp. or exp FLOCTAFENINE/ (216)
81. exp Meclofenamic Acid/ (2319)
82. meclofenam$.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer,
device trade name, keyword] (2769)
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83. oxaprozin.mp. or exp OXAPROZIN/ (658)
84. exp PIROXICAM/ or piroxicam.mp. (10561)
85. tenoxicam.mp. or exp TENOXICAM/ (1889)
86. tolmetin.mp. or exp TOLMETIN/ (2406)
87. or/67-86 (62118)
88. 66 or 87 (469269)
89. 24 and 35 and 88 (3792)
90. limit 89 to yr=“2014 - 2015” (394)
91. limit 89 to em=201414-201525 (396)
92. 90 or 91 (453)
Study design and animal filter used in the April 2014 search. The animal filter is revised in 2013 and line 31 is revised in 2014.
1 Clinical Article/
2 exp Clinical Study/
3 Clinical Trial/
4 Controlled Study/
5 Randomized Controlled Trial/
6 Major Clinical Study/
7 Double Blind Procedure/
8 Multicenter Study/
9 Single Blind Procedure/
10 Phase 3 Clinical Trial/
11 Phase 4 Clinical Trial/
12 crossover procedure/
13 placebo/
14 or/1-13
15 allocat$.mp.
16 assign$.mp.
17 blind$.mp.
18 (clinic$ adj25 (study or trial)).mp.
19 compar$.mp.
20 control$.mp.
21 cross?over.mp.
22 factorial$.mp.
23 follow?up.mp.
24 placebo$.mp.
25 prospectiv$.mp.
26 random$.mp.
27 ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).mp.
28 trial.mp.
29 (versus or vs).mp.
30 or/15-29
31 14 or 30
32 exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/
33 human/ or normal human/ or human cell/
34 32 and 33
35 32 not 34
36 31 not 35
May 2012 search strategy
1. Clinical Article/
2. exp Clinical Study/
3. Clinical Trial/
4. Controlled Study/
5. Randomized Controlled Trial/
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6. Major Clinical Study/
7. Double Blind Procedure/
8. Multicenter Study/
9. Single Blind Procedure/
10. Phase 3 Clinical Trial/
11. Phase 4 Clinical Trial/
12. crossover procedure/
13. placebo/
14. or/1-13
15. allocat$.mp.
16. assign$.mp.
17. blind$.mp.
18. (clinic$ adj25 (study or trial)).mp.
19. compar$.mp.
20. control$.mp.
21. cross?over.mp.
22. factorial$.mp.
23. follow?up.mp.
24. placebo$.mp.
25. prospectiv$.mp.
26. random$.mp.
27. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).mp.
28. trial.mp.
29. (versus or vs).mp.
30. or/15-29
31. 14 and 30
32. human/
33. Nonhuman/
34. exp ANIMAL/
35. Animal Experiment/
36. 33 or 34 or 35
37. 32 not 36
38. 31 not 36
39. 37 and 38
40. 38 or 39
41. dorsalgia.mp.
42. back pain.mp.
43. exp BACKACHE/
44. (lumbar adj pain).mp.
45. coccyx.mp.
46. coccydynia.mp.
47. sciatica.mp.
48. exp ISCHIALGIA/
49. spondylosis.mp.
50. lumbago.mp.
51. exp Low Back Pain/
52. or/41-51
53. exp Nonsteroid Antiinflammatory Agent/
54. nsaids.mp.
55. non-steroidal anti-inflammatory.mp.
56. exp Acetylsalicylic Acid/
57. acetylsalicyl$.mp.
58. carbasalate calcium.mp. or exp Carbasalate Calcium/
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59. diflunisal.mp. or exp DIFLUNISAL/
60. aceclofenac.mp. or exp ACECLOFENAC/
61. alclofenac.mp. or exp ALCLOFENAC/
62. diclofenac.mp. or exp DICLOFENAC/
63. exp INDOMETACIN/ or indometacin.mp.
64. sulindac.mp. or exp SULINDAC/
65. meloxicam.mp. or exp MELOXICAM/
66. exp PIROXICAM/ or piroxicam.mp.
67. dexibuprofen.mp. or exp DEXIBUPROFEN/
68. dexketoprofen.mp. or exp DEXKETOPROFEN/
69. exp FENOPROFEN/ or fenoprofen.mp.
70. flurbiprofen.mp. or exp FLURBIPROFEN/
71. ibuprofen.mp. or exp IBUPROFEN/
72. ketoprofen.mp. or exp KETOPROFEN/
73. naproxen.mp. or exp NAPROXEN/
74. tiapro$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug
manufacturer, device trade name, keyword]
75. metamizol.mp. or exp Dipyrone/
76. phenylbutazone.mp. or exp PHENYLBUTAZONE/
77. phenazone.mp. or exp PHENAZONE/
78. exp PROPYPHENAZONE/ or propyphenazone.mp.
79. celecoxib.mp. or exp CELECOXIB/
80. etoricoxib.mp. or exp ETORICOXIB/
81. exp Nabumetone/ or nabumeton.mp.
82. parecoxib.mp. or exp PARECOXIB/
83. or/53-82
84. exp Cyclooxygenase 2 Inhibitor/
85. rofecoxib.mp. or exp ROFECOXIB/
86. valdecoxib.mp. or exp VALDECOXIB/
87. lumiracoxib.mp. or exp LUMIRACOXIB/
88. etoricoxib.mp. or exp ETORICOXIB/
89. parecoxib.mp. or exp PARECOXIB/
90. vioxx.mp.
91. celebrex.mp.
92. bextra.mp.
93. prexige.mp.
94. arcoxia.mp.
95. etodolac.mp. or exp ETODOLAC/
96. floctafenine.mp. or exp FLOCTAFENINE/
97. exp Meclofenamic Acid/
98. meclofenam$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug
manufacturer, device trade name, keyword]
99. oxaprozin.mp. or exp OXAPROZIN/
100. exp PIROXICAM/ or piroxicam.mp.
101. tenoxicam.mp. or exp TENOXICAM/
102. tolmetin.mp. or exp TOLMETIN/
103. or/84-102
104. 83 or 103
105. 40 and 52 and 104
106. limit 105 to yr=“2007 - 2012”
107. limit 105 to em=200712-201220 1071
108. 106 or 107
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Appendix 5. Search strategies for clinical trials registries and PubMed
ClinicalTrials.gov
Last searched 24 June 2015.
Basic search: “back pain” and NSAIDS, received from 10 April 2014 to 24 June 2015.
May 2012 search strategy.
Condition: back pain AND Intervention: NSAID
WHO ICTRP
Last searched 24 June 2015.
Basic search: back pain and NSAIDS; we reviewed results from 2014 to 2015.
May 2012 search strategy.
Condition: back pain AND Intervention: NSAID
PubMed
Searched 24 June 2015.
((nsaids OR non-steroidal anti-inflammator* OR non-steroidal antiinflammator* OR aspirin OR acetylsalicyl* OR salicylic acid OR
carbasalate calcium OR diflunisal OR aceclofenac OR alclofenac OR diclofenac OR indomethacin OR indometacin OR sulindac
OR meloxicam OR piroxicam OR dexibuprofen OR dexketoprofen OR fenoprofen OR flurbiprofen OR ibuprofen OR ketoprofen
OR naproxen OR tiapro* OR metamizol OR phenylbutazone OR phenazone OR propyphenazone OR celecoxib OR etoricoxib OR
nabumeton OR parecoxib OR cyclooxygenase inhibitor* OR cyclo-oxygenase inhibitor* OR rofecoxib OR celecoxib OR valdecoxib
OR lumiracoxib OR etoricoxib OR parecoxib OR vioxx OR celebrex OR bextra OR prexige OR arcoxia OR etodolac OR floctafenine
OR Meclofenamic Acid OR meclofenamate OR meloxicam OR oxaprozin OR piroxicam OR tenoxicam OR tolmetin) AND (back
pain OR sciatica OR lumbar pain OR lumbago OR dorsalgia OR backache OR back disorder*) AND (pubstatusaheadofprint OR
publisher[sb] or pubmednotmedline[sb]))
Appendix 6. Criteria for assessing risk of bias for internal validity
Random sequence generation (selection bias)
Selection bias (biased allocation to interventions) due to inadequate generation of a randomized sequence
There is a low risk of selection bias if the investigators describe a random component in the sequence generation process such as: referring
to a random number table, using a computer random number generator, coin tossing, shuffling cards or envelopes, throwing dice,
drawing of lots, minimization (minimization may be implemented without a random element, and this is considered to be equivalent
to being random).
There is a high risk of selection bias if the investigators describe a non-random component in the sequence generation process, such
as: sequence generated by odd or even date of birth, date (or day) of admission, hospital or clinic record number; or allocation by
judgement of the clinician, preference of the participant, results of a laboratory test or a series of tests, or availability of the intervention.
Allocation concealment (selection bias)
Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment
There is a low risk of selection bias if the participants and investigators enrolling participants could not foresee assignment because
investigators used one of the following, or an equivalent method, to conceal allocation: central allocation (including telephone,
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internet-based and pharmacy-controlled randomization); sequentially numbered drug containers of identical appearance; or sequentially
numbered, opaque, sealed envelopes.
There is a high risk of bias if participants or investigators enrolling participants could possibly foresee assignments and thus introduce
selection bias, such as allocation based on: using an open random allocation schedule (e.g. a list of random numbers); assignment
envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or non-opaque or not sequentially numbered);
alternation or rotation; date of birth; case record number; or other explicitly unconcealed procedures.
Blinding of participants
Performance bias due to knowledge of the allocated interventions by participants during the study
There is a low risk of performance bias if trial investigators ensured blinding of participants and it was unlikely that the blinding could
have been broken; or if there was no blinding or incomplete blinding, but the review authors judge that the outcome is unlikely to be
influenced by lack of blinding.
Blinding of personnel/care providers (performance bias)
Performance bias due to knowledge of the allocated interventions by personnel/care providers during the trial
There is a low risk of performance bias if trial investigators ensured blinding of personnel and it was unlikely that blinding could have
been broken; or if there was no blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be
influenced by lack of blinding.
Blinding of outcome assessor (detection bias)
Detection bias due to knowledge of the allocated interventions by outcome assessors
There is low risk of detection bias if trial investigators ensured the blinding of the outcome assessment and it was unlikely that blinding
could have been broken; or if there was no blinding or incomplete blinding, but the review authors judge that the outcome is not likely
to be influenced by lack of blinding, or:
• for patient-reported outcomes in which the patient was the outcome assessor (e.g. pain, disability): there is a low risk of bias for
outcome assessors if there is a low risk of bias for participant blinding (Boutron 2005)
• for outcome criteria that are clinical or therapeutic events that will be determined by the interaction between patients and care
providers (e.g. co-interventions, length of hospitalisation, treatment failure), in which the care provider is the outcome assessor: there
is a low risk of bias for outcome assessors if there is a low risk of bias for care providers (Boutron 2005)
• for outcome criteria that are assessed from data from medical forms: there is a low risk of bias if the treatment or adverse effects
of the treatment could not be noticed in the extracted data (Boutron 2005).
Incomplete outcome data (attrition bias)
Attrition bias due to amount, nature or handling of incomplete outcome data
There is a low risk of attrition bias if there were no missing outcome data; reasons for missing outcome data were unlikely to be related
to the true outcome (for survival data, censoring unlikely to be introducing bias); missing outcome data were balanced in numbers,
with similar reasons for missing data across groups; for dichotomous outcome data, the proportion of missing outcomes compared
with the observed event risk was not enough to have a clinically relevant impact on the intervention effect estimate; for continuous
outcome data, the plausible effect size (difference in means or standardised difference in means) among missing outcomes was not
enough to have a clinically relevant impact on observed effect size, or missing data were imputed using appropriate methods (if drop-
outs are very large, imputation using even “acceptable” methods may still suggest a high risk of bias) (van Tulder 2003). The percentage
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of withdrawals and drop-outs should not exceed 20% for short-term follow-up and 30% for long-term follow-up and should not lead
to substantial bias (these percentages are commonly used but arbitrary, not supported by literature) (van Tulder 2003).
Selective reporting (reporting bias)
Reporting bias due to selective outcome reporting
There is low risk of reporting bias if the study protocol is available and all of the study’s pre-specified (primary and secondary) outcomes
that are of interest in the review have been reported in the pre-specified way, or if the study protocol is unavailable but it is clear that
the published reports include all expected outcomes, including those that were pre-specified (convincing text of this nature may be
uncommon).
There is a high risk of reporting bias if not all of the study’s pre-specified primary outcomes have been reported; one or more primary
outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not pre-specified; one or
more reported primary outcomes were not pre-specified (unless clear justification for their reporting is provided, such as an unexpected
adverse effect); one or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-
analysis; the study report fails to include results for a key outcome that would be expected to have been reported for such a study.
Group similarity at baseline (selection bias)
Bias due to dissimilarity at baseline for the most important prognostic indicators.
There is low risk of bias if groups are similar at baseline for demographic factors, value of main outcome measure(s), and important
prognostic factors (examples in the field of back and neck pain are duration and severity of complaints, vocational status, percentage
of patients with neurological symptoms) (van Tulder 2003).
Co-interventions (performance bias)
Bias because co-interventions were different across groups
There is low risk of bias if there were no co-interventions or they were similar between the index and control groups (van Tulder 2003).
Compliance (performance bias)
Bias due to inappropriate compliance with interventions across groups
There is low risk of bias if compliance with the interventions was acceptable, based on the reported intensity/dosage, duration, number
and frequency for both the index and control intervention(s). For single-session interventions (e.g. surgery), this item is irrelevant (van
Tulder 2003).
Intention-to-treat-analysis
There is low risk of bias if all randomized patients were reported/analysed in the group to which they were allocated by randomization.
Timing of outcome assessments (detection bias)
Bias because important outcomes were not measured at the same time across groups
There is low risk of bias if all important outcome assessments for all intervention groups were measured at the same time (van Tulder
2003).
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Other bias
Bias due to problems not covered elsewhere in the table
There is a low risk of bias if the study appears to be free of other sources of bias not addressed elsewhere (e.g. study funding).
WH A T ’ S N E W
Last assessed as up-to-date: 23 June 2015.
Date Event Description
12 July 2016 Amended Data extraction of the Kivitz article was not correct and has been adjusted. Conclusions have not change
H I S T O R Y
Review first published: Issue 2, 2016
Date Event Description
24 June 2015 New search has been performed We added the following databases to the search strategy: ClinicalTrials.gov, the
WorldHealthOrganization International Clinical Trials Registry Platform (2013)
, MEDLINE In-Process & Other Non-Indexed Citations (2014) and PubMed
(2015)
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S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• Dutch Arthritis Foundation, Netherlands.
This Cochrane review is partly funded by a Dutch Arthritis Foundation programme grant.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We excluded NSAIDs which are no longer available on themarket, such as rofecoxib, from this Cochrane review. We had not previously
stated this in the Cochrane protocol.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Anti-Inflammatory Agents, Non-Steroidal [adverse effects; ∗therapeutic use]; Chronic Pain [∗drug therapy]; Diclofenac [therapeutic
use]; Disability Evaluation; Ibuprofen [therapeutic use]; Indomethacin [therapeutic use]; Low Back Pain [∗drug therapy]; Pain Mea-
surement; Piroxicam [therapeutic use]; Randomized Controlled Trials as Topic
MeSH check words
Humans
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